Evidence Review – Surge Planning for Mental Health

Kim Donoghue, Rob Saunders & Stephen Pilling

March 2021

NATIONAL COLLABORATING CENTRE FOR MENTAL HEALTH

Contents

Executive Summary	3
Methods and data sources	4
Systematic review of systematic reviews	4
Analysis of incidence/prevalence rates from UK-based studies and datasets	4
Key findings	4
Limitations	5
Recommendations	5
Evidence from umbrella review:	6
Umbrella review	6
Research questions	6
Method	6
Search strategy	6
Study selection	7
Outcomes	7
Data extraction	7
Strategy for data synthesis	7
Analysis of subgroups	7
Results	9
Included studies	9
Anxiety	9
Depression	
Summary	
Prevalence and utilisation data from UK-based studies and services.	11
Common Mental Disorders (CMDs)	11
Prevalence	11
Utilisation	12
Potential at-risk sub-groups	14
Other mental health disorders and young people	20
Substance misuse	20
ADHD	20
Suicide/Self-harm/Abuse	20
Severe Mental Illness	21
Children and Young People	22

Executive Summary

The COVID-19 pandemic has an unprecedented impact on national and international healthcare systems. The consequences of governmental responses to the pandemics including national lockdowns, 'stay at home' orders and the requirements to quarantine¹, as well as fear of the effects of the virus, have been anticipated to create a substantial increase in the need for mental health support². However, there is uncertainty as to how and when this increase or surge in need will arrive, with primary care reporting decreases in referrals for individuals with mental health concerns, whilst antidepressant prescribing has increased³. The mental health impact of the pandemic may take time to be fully established, and it is likely that some groups of individuals will be more impacted than others. Being able to anticipate a potential surge in mental distress and the impact on the NHS, through identifying risk factors for increased needs, could help optimise the delivery of appropriate care for at-risk groups.

The aim of this review was to assess whether there is currently evidence of the COVID-19 Pandemic impacting on the incidence and prevalence of mental health problems in the UK, to identify potential risk-factors requiring consideration in the planning of future mental health service provision.

The following clinical areas were explored:

- → Common mental disorders (CMD)
- → Severe mental illness (SMI)
- ➔ Neurodevelopment disorders
- ➔ Substance misuse
- ➔ Dementia

The impact on the following areas was included in this review of the evidence:

- → Changing patterns of prevalence of mental health problems during the COVID-19 pandemic
- → Impact on mental health service utilisation during the COVID-19 pandemic
- → Differential impact of COVID-19 pandemic on subgroups:
 - Young people (aged 1-5, 6-13, 14-25)
 - o NHS and social care staff
 - o BME groups

¹ Greenberg, N., Docherty, M., Gnanapragasam, S., & Wessely, S. (2020). Managing mental health challenges faced by healthcare workers during COVID-19 pandemic. BMJ, 368, m1211. <u>https://doi.org/10.1136/bmj.m1211</u>

² Luykx, J. J., Vinkers, C. H., & Tijdink, J. K. (2020). Psychiatry in times of the coronavirus disease 2019 (COVID-19) pandemic: An imperative for psychiatrists to Act Now. JAMA Psychiatry, 77(11), 1097–1098. https://doi.org/10.1001/jamapsychiatry.2020.1225

³ Armitage, R (2021)...Antidepressants, primary care, and adult mental health services in England during COVID-19, The Lancet Psychiatry, 8(2),e3. https://doi.org/10.1016/S2215-0366(20)30530-7.

Methods and data sources

In order to review the available evidence in the timeframe, two distinct lines of enquiry were explored – firstly a systematic review of systematic reviews reporting on the prevalence of mental health conditions during the COVID-19 pandemic, focusing on UK-based studies, and secondly analysis of longitudinal general population cohort data, and data from mental health services.

Systematic review of systematic reviews

- → Search electronic databases CINAHL, Medline, PsycInfo and Embase
- → Include reviews using systematic methods
- → Extract evidence primarily from the UK, supplemented by European data where necessary.

Analysis of incidence/prevalence rates from UK-based studies and datasets

- ➔ Identify studies including standardised mental health measures, and calculate incidence of mental health problems where data is available.
- → Will focus on large longitudinal cohort studies for population-based incidence data.
- → Smaller datasets considered to explore sub-groups.

Data was drawn from 12 systematic reviews, a number cohort studies, and NHS databases.

Key findings

- The majority of the available data centred on common mental disorders (CMDs), with studies using validated measures of depression and generalised anxiety such as the PHQ-9 and GAD-7.
- Data from one longitudinal study, the UCL COVID-19 Social study⁴, showed that whilst depression and anxiety was slightly higher at the start of the pandemic, for the majority of people it was below clinical threshold, and decreased over time. This finding was replicated in other UK-based longitudinal studies.
- Data from Improving Access to Psychological Therapies (IAPT) services showed that nationally there was a decrease in both the number of referrals and patients entering treatment for CMDs at the start of the pandemic, and that the numbers referred and attending is still below pre-pandemic levels at present, although closer to pre-pandemic levels.
- There was limited published (and peer-reviewed) data on Severe Mental Illness (SMI), dementia, substance misuse and neurodevelopmental disorders. Available evidence, often from pre-publication manuscripts (therefore not peer-reviewed and formally published), indicated secondary care mental health service use initially decreased at the start of the pandemic (as seen in primary care) although there was little long-term data.
- Current evidence suggests that CMD is more prevalent in younger people and women, following pre-pandemic findings, and the differences between groups reminded consistent during the pandemic. Of note, data from one IAPT service suggested there had been no observable increase in referrals for younger people (18-24 years) during the pandemic.
- There was less available data on younger children, and findings were mixed. Some studies suggested small increases in CMDs, whereas others indicated potential gender differences. The lack of evidence indicates a need for further research in this population.
- For people of Ethnic Minority groups, the incidence of observable CMDs in the general population was higher than for White groups at all observed points during the pandemic.

⁴ Fancourt, D., Steptoe, A., & Bu, F. (2020a). Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: A longitudinal observational study. The Lancet Psychiatry, 8(2), 141–149. https://doi.org/10.1016/S2215-0366(20)30482-X

Whilst the proportion of referrals to a London IAPT service that are from Ethnic Minority groups has increase in the last year, it is in line with the pre-pandemic trend.

- The evidence on the impact for health and social care workers was less clear. Data from cohort studies indicated slightly higher rates of CMD, especially depression, in health and social care workers in the most recent months. Evidence from reviews suggested higher prevalence in frontline health and social care workers compared to non-frontline health and social care workers, and studies on specific groups of workers such as ICU staff have suggested increased PTSD prevalence⁵.
- The group found to demonstrate the highest incidence of CMDs were people who had previously been diagnosed with a mental health condition, who appear to be particularly vulnerable.

Limitations

- The systematic review identified existing reviews of the literature, and observed limited research exploring non-CMD prevalence. A number of UK-based studies were identified only through preprint servers, which means they are currently undergoing peer-review and therefore are not formally published. This suggests additional evidence is likely to be available over the coming months, indicating a need to systematically explore the area on a re-occurring basis. In addition many studies report data on the first 6-8 months of the pandemic. As such, the impact of aftermath of the first wave and the impact of the second wave will not be seen in much of the data reviewed
- Data from general population studies are likely to have biased samplings, despite attempts for stratified sampling and use of survey weights, and therefore harder to reach groups who may have more severe mental problems may not be present in the data.
- Nationally published mental health data, such as IAPT, is currently available only in aggregate form and does not include data on potential risk factors such as age and ethnicity groups. Utilising data from local services in this report could limit the generalisability of findings.
- There is the potential for risk factors such as changes in employment and income, as well as the longer term impact of changes of the furlough policy, to negatively impact on mental health, but the current data limited exploration of this issue.
- Some disorders may take time to present to services, for example people with PTSD may not present to services for some considerable time after the exposure to trauma.
- Whilst referrals to services may have decreased, it is has been suggested that the severity of illness may have increased due to pandemic related constraint on access to effective treatment.

Recommendations

• Whilst the rate of mental health problems has not shown a consistent increase in the studies reviewed, further monitoring through general population studies and trends in mental health service utilisation should be considered to identify changes in demand, particularly for those with existing disorders or who are at-risk group.

⁵ Greenberg, N., Weston, D., Hall, C., Caulfield, T., Williamson, V., & Fong, K. (2021). Mental health of staff working in intensive care during COVID-19. Occupational Medicine. Advance online publication. https://doi.org/10.1093/occmed/kqaa220

- Reviews of the available evidence conducted at routine time points would synthesise the emerging literature, especially for non-CMD prevalence, and take into account the 'time lag' for the presentation of some disorders.
- Exploring the severity/acuity of presentations to services, rather than just the observed count might optimise support and surge planning.
- The impact of potential for risk factors such as negative changes in employment status and income (which are known to impact on mental health), as well as the impact of changes of the furlough policy, should be considered in any future reviews
- Data on children and young people is across the 0-25 age range is very limited. Given the long-term consequence of many childhood disorders this should be a priority for future reviews.
- Data on older people, in particular those with dementia, and those with neurodevelopmental disorders across the age range is also very limited and again should be a priority for future reviews.

Evidence from umbrella review:

Umbrella review

This review, "The impact of the COVID-19 pandemic on mental health: an umbrella review" has been registered on the International prospective register of systematic reviews, PROSPERO (registration number: CRD42021244866).

Research questions

- 1. What is the prevalence of mental health problems during the covid-19 pandemic?
 - a. Common mental health conditions
 - b. Severe mental illness
 - c. Neurodevelopmental disorders
 - d. Substance misuse
 - e. Dementia
- 2. Has there been a change in the pattern of prevalence of mental health problems over time during the COVID-19 pandemic?
- 3. Has there been an impact on mental health service utilisation during the COVID-19 pandemic?
- 4. Has there been a disproportionate impact of the COVID-19 pandemic on specific characteristics or vulnerable groups? Specifically;
 - a. young people (aged 1-5, 6-12, 16-25),
 - b. NHS and social care staff
 - c. Black, Asian and Minority Ethnic groups

Method

This review of reviews (umbrella review) was completed in accordance with the World Health Organisation Rapid Reviews to strengthen Health Policy and systems: A Practical Guide.

Search strategy

Electronic databases MEDLINE (Ovid), PsycInfo (Ovid), Embase (Ovid), CINAHL and the Cochrane library will be searched. These searches will be supplemented with manual searching of included

reviews bibliographies and medRxiv. Searches will be limited to English language and publication after December 2019. Searches include key terms relating to mental health conditions, the COVID-19 pandemic and systematic reviews (please see appendices for full search strategies).

Study selection

Reviews of any population affected by the COVID-19 pandemic will be included, reporting prevalence of mental health symptoms, according to diagnostic criteria or a validated scale and cutoff, crosssectionally or longitudinally will be included. Reviews addressing the utilisation of mental health services will also be included. Systematic reviews (including rapid systematic reviews) with or without meta-analyses will be considered for inclusion. Reviews will be considered for inclusion if they have searched at least 3 databases and include a quality assessment.

Outcomes

Systematic reviews will be identified that have reported at least one of the following; 1. Prevalence of mental health symptoms before and/or during the COVID-19 pandemic, 2. Rates of mental health service use before and/or during the COVID-19 pandemic.

Data extraction

One reviewer will screen the titles and abstracts of all identified references. The full texts of potentially relevant guidelines will be screened by the same reviewer. Data from each relevant review will be extracted using Microsoft Excel spreadsheets that have been pre-piloted.

For all included reviews, the following information will be extracted;

- 1. Author and year of publication
- 2. Search strategy (databases searched, dates of searches, inclusion/exclusion criteria)
- 3. Setting (type of mental health service)
- 4. Included publication details (number of included studies, country where studies was conducted, list of included studies, study designs, population details (e.g. general population, healthcare staff etc))
- 5. Participant details (number of participants, gender, ethnicity, age, mental health diagnosis)


Strategy for data synthesis

This will be comprised of a narrative synthesis of the extracted data population characteristics and type of outcome. The prevalence of mental health problems and the rates of service utilisation will be compared across reviews.

Analysis of subgroups

The impact of the COVID-19 pandemic on the mental health of specific sub groups is largely unknown. If there is available data, the prevalence of mental health problems and rates of service utilisation in vulnerable populations, including young people, Black, Asian and Minority ethnic groups, healthcare staff will be considered.

Figure 1: PRISMA diagram



Results

Included studies

A total of 12 systematic reviews met inclusion criteria for this umbrella review (see PRISMA diagram). The characteristics and results of the included reviews are reported in table A6 and A7 in the appendices. These studies only reported on rates of depression or anxiety, with no reviews of SMI, substance misuse, neurodevelopmental disorders or dementia identified.

Anxiety

The pooled prevalence for anxiety reported in the included reviews ranged from 15.15% to 34%. Two reviews compared the prevalence of anxiety in healthcare staff and the general population and found no difference^{6,7}. A review by Chen et al⁸, found a higher prevalence of anxiety in frontline staff (28%) compared to general healthcare workers (22%). One review found that those with pre-existing mental and physical health conditions had a higher prevalence of anxiety⁶. There was no evidence in the reviews to suggest a difference in prevalence rates for gender or age⁹.

Three reviews included studies that assessed anxiety pre and post the pandemic onset^{10,11,12}. Small but significant increases in anxiety have been found (e.g. anxiety pre to post pandemic (SMC = .125 [95% CI: .019 to .230], z = 2.31, p = .021).¹⁰

The UK only data was extracted from the included reviews and the results were largely similar with the prevalence of anxiety reported as between 24.4% and 34% and small increases in anxiety scores.

⁶ Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis. Psychiatry Research. 2020;291:113190.

⁷ Cenat JM, Blais-Rochette C, Kokou-Kpolou CK, Noorishad PG, Mukunzi JN, McIntee SE, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Research. 2021;295:113599.

⁸ Chen X, Chen J, Zhang M, Chen RZ, Dong RK, Dong Z, et al. One Year of Evidence on Mental Health in the COVID-19 Crisis-A Systematic Review and Meta-Analysis. medRxiv. 2021.

⁹ Wang Y, Kala MP, Jafar TH. Factors associated with psychological distress during the coronavirus disease 2019 (COVID-19) pandemic

on the predominantly general population: A systematic review and meta-analysis. PLoS ONE [Electronic Resource]. 2020;15(12):e0244630. ¹⁰ Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic. medRxiv. 2021.

¹¹ Thombs BD, Bonardi O, Rice DB, Boruff JT, Azar M, He C, et al. Curating evidence on mental health during COVID-19: A living systematic review. Journal of Psychosomatic Research. 2020;133:110113.

¹² Hessami K, Romanelli C, Chiurazzi M, Cozzolino M. COVID-19 pandemic and maternal mental health: a systematic review and metaanalysis. Journal of Maternal-Fetal & Neonatal Medicine. 2020:1-8.

Depression

The pooled prevalence of depression ranged from 15.97% to 28%. Two reviews reported the prevalence of depression in healthcare staff compared to the general population and found no difference¹³¹⁴. One review reported that a higher prevalence of depression in frontline staff compared to general healthcare staff (20% vs 15%). Luo et al.¹⁵ reported a higher prevalence of depression in those with pre-existing mental and physical health conditions compared to healthcare workers and the general population. There was no evidence in the reviews to suggest a difference in the prevalence of depression for gender or age¹⁶

Three reviews included studies that assessed depression pre and post the pandemic onset¹⁷¹⁸¹⁹. There was a small significant increase in symptoms of depression pre to post pandemic outbreak (SMC = .216 [95% CI: .135 to .296], z = 5.24, p < .001)²⁰

The UK only data was extracted from the reviews with studies reporting the prevalence of depression as between 15% and 31.4% and a small increase in depression was seen pre to post pandemic onset.

Summary

This umbrella review identified 12 reviews of the prevalence of mental health problems during the COVID-19 pandemic, all of which looked at common mental disorders. Increases during the pandemic were identified as small, and people with previously diagnosed mental health conditions were observed to be most at-risk, alongside frontline healthcare workers (but not non-frontline workers) noted to be possible increased risk.

¹³ Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis. Psychiatry Research. 2020;291:113190.

¹⁴ Cenat JM, Blais-Rochette C, Kokou-Kpolou CK, Noorishad PG, Mukunzi JN, McIntee SE, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Research. 2021;295:113599.

¹⁵ Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis. Psychiatry Research. 2020;291:113190.

¹⁶ Wang Y, Kala MP, Jafar TH. Factors associated with psychological distress during the coronavirus disease 2019 (COVID-19) pandemic on the predominantly general population: A systematic review and meta-analysis. PLoS ONE [Electronic Resource]. 2020;15(12):e0244630.

¹⁷ Thombs BD, Bonardi O, Rice DB, Boruff JT, Azar M, He C, et al. Curating evidence on mental health during COVID-19: A living systematic review. Journal of Psychosomatic Research. 2020;133:110113.

¹⁸ Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic. medRxiv. 2021.

¹⁹ Hessami K, Romanelli C, Chiurazzi M, Cozzolino M. COVID-19 pandemic and maternal mental health: a systematic review and metaanalysis. Journal of Maternal-Fetal & Neonatal Medicine. 2020:1-8.

²⁰ Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic. medRxiv. 2021.

Prevalence and utilisation data from UK-based studies and services.

Common Mental Disorders (CMDs)

The majority of cohort studies exploring mental health status during the pandemic have included only measures of CMDs. In this section of the report, data on the prevalence of CMDs is taken from the UCL COVID-19 Social Study, a longitudinal cohort study following the impact of the pandemic on mental health and wellbeing in the UK general population²¹. Raw data was provided by the study's principle investigator, which was analysed for the current report. The main findings from the COVID-19 Social Study have been replicated in other UK-based longitudinal cohort studies, and further data presented in this report has not been formally published by the study team at present.

Data on mental health service utilisation for CMD related distress is taken from the Improving Access to Psychological Therapies (IAPT) services. These national services provided evidence-based psychological treatment for CMDs, and received over 1.6 million referrals in the year proceeding the pandemic. National aggregate data is reported by NHS Digital²², and further data on referral numbers by patient demographics (e.g. age, gender, ethnicity) was provided by an IAPT service in London which forms part of the UCL North and Central East London IAPT Service Improvement and Research Network (NCEL IAPT SIRN)²³.

Prevalence

Figure 2 presents the average Patient Health Questionnaire (9-items)²⁴ and Generalised Anxiety Disorder scale (7-items)²⁵ each month from March 2020 (start of the first national lockdown) until March 2021, collected as part of the UCL COVID-19 Social Study. The highest scores were observed early on in the pandemic, fell and then levelled off after summer 2020. However, the average score was below the threshold for clinically observable depression/anxiety (a score of above 10 on both measures) for all months. It should be noted that the study moved from weekly to monthly collection of data from participants from August 2020, and therefore it is possible the increase into September was associated with this change in methodology.

The proportion of scores above the clinical thresholds on each measure was 23% (GAD-7) and 27% (PHQ-9) in March 2020, which decreased to 11% (GAD-7) and 16% (PHQ-9) in August 2020 and was at 14% (GAD-7) and 22% (PHQ-9) in March 2021.

²¹ Fancourt, D., Steptoe, A., & Bu, F. (2020a). Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in England: A longitudinal observational study. The Lancet Psychiatry, 8(2), 141–149. https://doi.org/10.1016/S2215-0366(20)30482-X

 $^{^{22}\} https://digital.nhs.uk/data-and-information/publications/statistical/psychological-therapies-report-on-the-use-of-iapt-services$

²³ Saunders, R., Cape, J., Leibowitz, J., ... Buckman, J. E. J. (2020). Improvement in IAPT outcomes over time: Are they driven by changes in clinical practice? Cognitive Behaviour Therapist, 13, e16. https://doi.org/10.1017/S1754470X20000173

²⁴ Kroenke, K., Spitzer, R. L., & Williams, J. B.W. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16, 606–613.

²⁵ Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder. Archives of Internal Medicine, 166(10), 1092. https://doi.org/10.1001/archinte.166.10.1092




Figure 2: Mean PHQ-9 and GAD-7 scores each month for participants of the UCL COVID-19 Social Study (data accessed with permission from Dr Daisy Fancourt).

Data from another UK-based longitudinal study (the UK Household Longitudinal Survey) included data from before the pandemic, and suggested a small increase in average General Health Questionnaire (GHQ) scores in May 2020 compared to the previous year. Scores then decreased to October 2020, although the score was still slightly higher than pre-pandemic levels²⁶

Utilisation

The number of referrals and people entering treatment at all IAPT services in England before and during the pandemic (to Dec 2020) is presented in Figure 3. There was a significant decrease in the number of referrals in March and April 2020 corresponding with the first national lockdown, followed by a steady increase in referrals. The number of referrals is currently below that of previous years, although the number entering treatment is reported to be at the same level.

²⁶ Preprint: Pierce, M, McManus, S...& Abel, K (2021). Different Mental Health Responses to the COVID-19 Pandemic: Latent Class Trajectory Analysis Using Longitudinal UK Data. Available at SSRN: https://ssrn.com/abstract=3784647 or http://dx.doi.org/10.2139/ssrn.3784647




Figure 3. Count of monthly referrals to IAPT services in England between Oct 2018 and Dec 2020 (data accessed through the NHS Digital IAPT reporting website – by monthly extract²⁷).

 $^{^{27}\} https://digital.nhs.uk/data-and-information/publications/statistical/psychological-therapies-report-on-the-use-of-iapt-services$

Potential at-risk sub-groups

The incidence and rate of utilisation for CMDs by potentially at-risk sub-groups was explored using data from both the COVID-19 Social study and from a London-based IAPT service which provided referral data by patient demographics.

Age

The proportion of participants above the clinical threshold on the PHQ-9 and GAD-7 scores for different age groups is presented in figure 4, and indicates increasing levels of average mental health symptomatology as age increases. Younger people are reported to have been most affected by the pandemic, both through reduced social interaction as well as being more vulnerable to employment changes, and the data suggests this group have the highest incidence of clinically significant depression and anxiety.




Figure 4: Proportion of participants by age group scoring above the clinical thresholds on the PHQ-9 and GAD-7. Source: the UCL COVID-19 Social Study (data accessed with permission from Dr Daisy Fancourt).

The number of referrals to an IAPT service in central London by age group is presented in figure 5 and shows that 25-45 year olds made up the majority of referrals both before and during the pandemic. The higher incidence of depression and anxiety in the general population for younger people has not been associated with an increased number of referrals to this IAPT service for this age group, as the trend appears constant for this group.




Figure 5. Count of monthly referrals to an IAPT March 2019 and Feb 2021 (data provided by the City & Hackney IAPT service).

Gender

The incidence of clinically significant depression and anxiety has been higher in women compared to men through the pandemic (figure 6). The likelihood of women reporting clinically significant anxiety was nearly double that of men in March 2020, but this difference has decreased during the pandemic.




Figure 6: Proportion of participants by gender scoring above the clinical thresholds on the PHQ-9 and GAD-7. Source: the UCL COVID-19 Social Study (data accessed with permission from Dr Daisy Fancourt).

The rate of referrals to IAPT services between men and women has not differed during the pandemic. Data shows that around 70% of referrals were for women pre-COVID, and this proportion

has remained relatively constant through the pandemic, even in the months of reduced referrals (Figure 7).




Figure 7. Proportion of male and female referrals to an IAPT between March 2019 and Feb 2021 (data provided by the City & Hackney IAPT service).

Ethnicity

People from Black and Minority Ethnic (BME) groups have also been identified as a potentially vulnerable group for both contracted COVID-19 but also associated impact on mental health and wellbeing. Data from the UCL COVID-19 Social Study indicates that the likelihood of scoring in the clinical range of the PHQ-9 and GAD-7 is higher in people from BME groups than white groups through the pandemic (figure 8).





Figure 8: Proportion of participants by ethnicity group scoring above the clinical thresholds on the PHQ-9 and GAD-7. Source: the UCL COVID-19 Social Study (data accessed with permission from Dr Daisy Fancourt).

However, individuals from White ethnic groups still make up the majority of referrals to IAPT services. The proportion of referrals that are from BME groups has increased during the pandemic,



but this trend was observed pre-COVID (figure 9), and suggests that there has not be an observable increase for BME groups during the pandemic at this IAPT service.

Figure 9. Proportion of White and BME referrals to an IAPT between March 2019 and Feb 2021 (*data provided by the City & Hackney IAPT service*).

Previously diagnosed mental health condition

Individuals who reported they had previously been diagnosed with a mental health condition were found to be more at risk of scoring in the range for clinically significant depression and anxiety throughout the pandemic using data from the COVID-19 Social Study. Figure 10 shows that over 50% of participants who self-reported having a mental health diagnosis scored above 10 on the PHQ-9 for the majority of the observed study period, and that 40% scored above the threshold on the GAD-7 for most months.




Figure 10: Proportion of participants by previous mental health diagnosis status scoring above the clinical thresholds on the PHQ-9 and GAD-7. Source: the UCL COVID-19 Social Study (data accessed with permission from Dr Daisy Fancourt).

As part of the COVID-19 social study, participants were asked an individual self-report question as to whether they thought their mental health was 'worse', 'the same' or 'better' during the first national lockdown compared to before. Whilst 29% of people without a previous mental health disorder said

their mental health was worse, 50% of participants who reported previous mental health diagnosis said their mental health was worse (see Table 1). Interestingly more participants with a previous diagnosis said their mental health was "better" (13%) than people without a diagnosis (7%). This may be because some individuals with an existing disorder such as social anxiety and/or with work-related stressors benefitted from the national lockdown and the reduced pressure of interacting with others or being in more stressful environments.

		Wor	Worse		Same		Better	
	n	n	%	n	%	n	%	
Full Sample	29154	9587	33	17278	59	2289	8	
No previous MH diagnosis	24346	7171	29	15510	64	1665	7	
With previous MH Diagnosis	4808	2416	50	1768	37	624	13	

Data from two IAPT services in London showed that the average GAD-7 scores of all patients in contact with the service increased in the first weeks of lockdown compared to the average over the previous three years, before returning to the same level as previous years (figure 11). The level of anxiety then appeared to increase slightly as lockdown restrictions were lifted towards the end of June²⁸. Interestingly the average PHQ-9 score decreased in the first weeks of the initial lockdown for people in contact with the IAPT services, before returning to the same level as the previous years, and again increasing as restrictions were eased.




Figure 11. Average weekly GAD-7 and PHQ-9 scores in two IAPT services in London.

Health or social care workers

The incidence of clinically significant depression and anxiety between participants reporting they were health or social care workers is presented in figure 12. The likelihood of scoring 10 or more on the PHQ-9 and GAD-7 was around 3% and 2% higher in healthcare workers than non-healthcare

²⁸ Saunders, R., Buckman, J. E. J., Leibowitz, J., Cape, J., & Pilling, S. (2021) Trends in depression & anxiety symptom severity in mental health service attendees during the COVID-19 pandemic. https://doi.org/10. 31219/osf.io/eprqn

workers, respectively. A study conducted on ICU staff found that 40% of over 700 workers met criteria for PTSD, compared to 6% for severe depression and 11% for anxiety, suggesting this group may be at particular risk of trauma-related distress²⁹.




Figure 12: Proportion of participants by healthcare worker status scoring above the clinical thresholds on the PHQ-9 and GAD-7. Source: the UCL COVID-19 Social Study (data accessed with permission from Dr Daisy Fancourt).

²⁹ Greenberg, N, Weston, D....Fong, K. (2021). Mental health of staff working in intensive care during COVID-19, Occupational Medicine/ https://doi.org/10.1093/occmed/kqaa220

Other mental health disorders and young people

Owing to the lack of identified reviews of mental health disorders and symptoms other than CMDs, electronic searches were performed to identify any studies that have looked at other mental health disorders, including substance misuse, SMI and neurodevelopmental disorders.

Substance misuse

There is limited evidence available on the impact of the COVID-19 pandemic on drug and alcohol misuse. A cross-sectional³⁰ survey suggests that high risk drinking (Audit -C score 5+) has increased following the introduction of lockdown measures in March 2020 (25.1% versus 38.3%, OR = 1.85, CI = 1.67-2.06). A cohort study³¹ of men aged 50 found high-risk drinking increased from 19.4% to 24.6% between 2016–2018 and May 2020, a statistically significant increase of 5.2 percentage points (95% CI=2.5, 8.0, p<0.001). Only one study in the UK with people who inject drugs was identified³². This cross-sectional unlinked anonymous survey found higher levels of cocaine (25% vs 17%; P = 0.011) and amphetamine (17% vs 11%; P = 0.034) injection in the last month compared to those who completed the 2019 survey. Survey respondents also reported greater difficulties accessing drug/alcohol services, equipment to safely inject drugs, substitute drug treatment and accessing blood-borne virus testing.

ADHD

A cross-sectional parent reported study completed in the UK³³ investigated the potential impact of the COVID-19 pandemic on the mental health of children and young people with a neurodevelopmental disorder compared a pre-COVID clinical mental health sample. Higher emotional symptoms, conduct problems and hyperactivity was reported in the post COVID group and lower prosocial behaviour. In a small cross-sectional survey³⁴ (N=24) of adults with ADHD, during the COVID-19 pandemic period the mean GAD-7 score (anxiety) was 4.84 (SD 1.46), the mean PHQ-9 score (depression) was 10.88 (SD 6.83).

Suicide/Self-harm/Abuse

An international, online cross-sectional survey completed March/April 2020 reported that the UK had lowest prevalence of suicidal ideation (0.7%), assessed with the PHQ³⁵. The COVID-19 social study³⁶ found that 18% of participants in the survey reported experiencing thoughts of suicide or self-harm in the first month of lockdown in the UK. Around 60% of participants engaging in self-harm behaviours and 40% of participants with self-harm/suicidal thoughts or reporting abuse had accessed at least one type of formal or structured mental health support during the first month of lockdown (most commonly psychiatric medications). A large population-based cohort study³⁷ using

³⁰ Jackson SE, Garnett C, Shahab L, Oldham M, Brown J. Association of the COVID-19 lockdown with smoking, drinking and attempts to quit in England: an analysis of 2019-20 data. Addiction. 2020;21:21.

³¹ Daly M, Robinson E. High-Risk Drinking in Midlife Before Versus During the COVID-19 Crisis: Longitudinal Evidence From the United Kingdom. American Journal of Preventive Medicine. 2021;60(2):294-7.

³² Croxford S, Emanuel E, Ibitoye A, Njoroge J, Edmundson C, Bardsley M, et al. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. Public Health. 2021;192:8-11.

³³ Nonweiler J, Rattray F, Baulcomb J, Happe F, Absoud M. Prevalence and Associated Factors of Emotional and Behavioural Difficulties during COVID-19 Pandemic in Children with Neurodevelopmental Disorders. Children. 2020;7(9):04.

³⁴ Adamou M, Fullen T, Galab N, Mackintosh I, Abbott K, Lowe D, et al. Psychological Effects of the COVID-19 Imposed Lockdown on Adults with Attention Deficit/Hyperactivity Disorder: Cross-Sectional Survey Study. JMIR Formative Research. 2020;4(12):e24430.

³⁵ Cheung T, Lam SC, Lee PH, Xiang YT, Yip PSF, International Research Collaboration on C. Global Imperative of Suicidal Ideation in 10 Countries Amid the COVID-19 Pandemic. Frontiers in psychiatry Frontiers Research Foundation. 2020;11:588781.

³⁶ Iob E, Steptoe A, Fancourt D. Abuse, self-harm and suicidal ideation in the UK during the COVID-19 pandemic. British Journal of Psychiatry. 2020;217(4):543-6.

³⁷ Carr MJ, Steeg S, Webb RT, Kapur N, Chew-Graham CA, Abel KM, et al. Effects of the COVID-19 pandemic on primary care-recorded mental illness and self-harm episodes in the UK: a population-based cohort study. The lancet Public Health. 2021;6(2):e124-e35.

electronic Primary Care records found the incidence of self-harm was 37.6% (34.8%–40.3%) lower than expected in April, 2020, and the reduction was greatest for women and individuals aged younger than 45 years. A retrospective cohort study using electronic patient records from 23 hospital emergency departments in 10 countries (including the UK)³⁸, emergency psychiatric hospital presentations decreased from 1239 in 2019 to 834 in 2020, incident rate ratio 0.67, 95% CI 0.62–0.73; *p* < 0.001. The proportion of children and adolescents presenting with self-harm increased from 50% in 2019 to 57% in 2020, odds ratio 1.33, 1.07–1.64; *p* = 0.009 but there was no difference in the proportion presenting with severe self-harm.

The COVID-19 Social Study³⁹ reported that 18% of those surveyed reported experiencing psychological or physical abuse and around 50% of these people experienced thoughts of suicide or self-harm, and 25% of them had engaged in self-harm behaviours during the previous week. Data collected on patients presenting with traumatic penetrating injuries at King's College Hospital in South London during the first lockdown period (23rd March – 29th April 2020) shows an overall drop in trauma presentations from 2018 (48 to 30). The number of trauma presentations due to interpersonal violence dropped from 46 in 2018 to 19 in 2020. Incidents of self-harm rose from 1 in 2018 to 8 in 2020⁴⁰.

Severe Mental Illness

There was a 40% reduction in the number of referrals in 2020 to an inpatient liaison psychiatry department in South London in the UK comparted to the same period in 2019. No evidence for high rates of new-onset acute mental illness was found⁴¹. Retrospective, electronic case record data from Leicestershire Partnership NHS Trust recording referrals to mental health services and admissions to psychiatric hospital reported that total admissions reduced from 315 pre-lockdown to 210 post lockdown. CAMHS, PICU and intellectual disabilities were exceptions to this, and small increases in admissions were seen. Statistically significant (P < 0.05) decreases in admissions were observed for acute mental health services for adults (pre-lockdown n = 152; lockdown n = 121), as well as MHSOP (pre-lockdown period, to 4622 in the lockdown period. Referrals to all service types within Core AMH reduced significantly (P < 0.05), except the forensic service, where there was a slight increase (pre-lockdown n = 51; lockdown n = 64).

Chen et al. (2020)⁴² completed an interrupted time series study using electronic clinical records data from of Cambridgeshire and Peterborough NHS Foundation Trust. There was a drop in mental health referrals following the initial COVID-19 lockdown but then a longer-term increase in the referral rate (by 1.21 referrals per day per day, 95% confidence interval [CI] 0.41–2.02). This increase was primarily for urgent or emergency referrals (0.96, CI 0.39–1.54), including referrals to liaison psychiatry (0.68, CI 0.35–1.02) and mental health crisis teams (0.61, CI 0.20–1.02). The increase was

³⁸ Ougrin D, Wong BHC, Vaezinejad M, Plener PL, Mehdi T, Romaniuk L, et al. Pandemic-related emergency psychiatric presentations for self-harm of children and adolescents in 10 countries (PREP-kids): a retrospective international cohort study. European Child and Adolescent Psychiatry. 2021.

³⁹ Iob E, Steptoe A, Fancourt D. Abuse, self-harm and suicidal ideation in the UK during the COVID-19 pandemic. British Journal of Psychiatry. 2020;217(4):543-6.

⁴⁰ Olding J, Zisman S, Olding C, Fan K. Penetrating trauma during a global pandemic: Changing patterns in interpersonal violence, selfharm and domestic violence in the Covid-19 outbreak. Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh & Ireland. 2021;19(1):e9-e13.

⁴¹ Butler M, Delvi A, Mujic F, Broad S, Pauli L, Pollak TA, et al. Reduced Activity in an Inpatient Liaison Psychiatry Service During the First Wave of the COVID-19 Pandemic: Comparison With 2019 Data and Characterization of the SARS-CoV-2 Positive Cohort. Frontiers in psychiatry Frontiers Research Foundation. 2021;12:619550.

⁴² Chen, S., She, R., ... & Cardinal, R. N. (2020). The Medium-Term Impact of COVID-19 Lockdown on Referrals to Secondary Care Mental Health Services: A Controlled Interrupted Time Series Study. Frontiers in psychiatry, 11, 585915. https://doi.org/10.3389/fpsyt.2020.585915

significant for females (0.56, CI 0.04–1.08), males (0.64, CI 0.05–1.22), working-age adults (0.93, CI 0.42–1.43), people of White ethnicity (0.98, CI 0.32–1.65), those living alone (1.26, CI 0.52–2.00), and those who had pre-existing depression (0.78, CI 0.19–1.38), severe mental illness (0.67, CI 0.19–1.15), hypertension/cardiovascular/cerebrovascular disease (0.56, CI 0.24–0.89), personality disorders (0.32, CI 0.12–0.51), asthma/chronic obstructive pulmonary disease (0.28, CI 0.08–0.49), dyslipidemia (0.26, CI 0.04–0.47), anxiety (0.21, CI 0.08–0.34), substance misuse (0.21, CI 0.08–0.34), or reactions to severe stress (0.17, CI 0.01–0.32). No significant post-lockdown increase was observed for children/adolescents, older adults, people of ethnic minorities, married/cohabiting people, and those who had previous/pre-existing dementia, diabetes, cancer, eating disorder, a history of self-harm, or intellectual disability. An additional study found observable decreases in the number of referrals to secondary adult mental health services, as well as to intellectual disability services following lockdown which was below pre-pandemic levels by the middle of May 2020⁴³. The number of absolute admissions was small in the dataset but indicated that there was a sharp decrease in the first weeks of lockdown, which returned to the same level within the following 6 to 8 weeks.

Children and Young People

The available research on the impact of COVID-19 on children and young people's mental health in the UK presents a mixed picture⁴⁴. UK based parents and carers of school aged children and young people aged between 4 and 16 completed an online survey at two time points between March and May 2020. For children aged 4-10, there were increases in caseness for emotional symptoms and hyperactivity/inattention. The proportion of adolescents classified as a case did not change significantly for emotional symptoms, conduct problems, or hyperactivity/ inattention⁴⁵. A UK population-based birth cohort of children aged 11-12 and their mothers collected data between December 2019 and March 2020 and again 3 months after lockdown. Children reported a 44% increase in their symptoms of depression (p < 001), and a 26% increase in PTSD symptoms⁴⁶. An ongoing NIHR survey study found that amongst students aged 13-14 (n=1047), there was an overall decrease in the proportion of students at risk of anxiety during lockdown, with girls' falling from 54% to 45% and boys from 26% to 18%, compared to pre-lockdown. There was a small increase in girls at risk of depression from 31% pre-pandemic to 34% during lockdown, but a small decrease in boys at risk of depression from 21% pre-pandemic to 19% during lockdown⁴⁷. Referrals to Child and Adolescent services showed a limited decrease over the observed time period in a study exploring the first 8 weeks of lockdown⁴³.

Open, 6(6), E117. https://doi.org/10.1192/bjo.2020.104

⁴³ Tromans, S., Chester, V., Harrison, H., Pankhania, P., Booth, H., & Chakraborty, N. (2020). Patterns of use of secondary mental health services before and during COVID-19 lockdown: Observational study. BJPsych

⁴⁴ <u>https://emergingminds.org.uk/wp-content/uploads/2021/03/01-Gayer-Anderson.pdf</u>

⁴⁵ Waite P, Pearcey S, Shum A, Raw J, Patalay P, Creswell C. How did the mental health of children and adolescents change during early lockdown during the COVID-19 pandemic in the UK?.

⁴⁶ Wright N, Hill J, Sharp H, Pickles A. Impact of COVID-19 on Young Adolescent Mental Health: Comparison of Depression, Anxiety and Behaviour Problems in 12 Year Olds Immediately Before and During the Pandemic in a UK Birth Cohort. Anxiety and Behaviour Problems in. 2020 Oct 26;12.

⁴⁷ Widnall E, Winstone L, Mars B, Haworth C, Kidger J. Young people's mental health during the COVID-19 pandemic: Initial findings from a secondary school survey study in South West England. National Institute for Health Research School for Public Health Research. 2020.

Appendices

Table A1: OVID Medline search strategy

1	EATING DISORDERS/ or ANOREXIA NERVOSA/ or BINGE-EATING DISORDER/ or BULIMIA
	NERVOSA/ or FEMALE ATHLETE TRIAD SYNDROME/ or PICA/
2	HYPERPHAGIA/ or BULIMIA/
3	SELF-INJURIOUS BEHAVIOR/ or SELF MUTILATION/ or SUICIDE/ or SUICIDAL IDEATION/ or
	SUICIDE, ATTEMPTED/
4	MOOD DISORDERS/ or AFFECTIVE DISORDERS, PSYCHOTIC/ or BIPOLAR DISORDER/ or
	CYCLOTHYMIC DISORDER/ or DEPRESSIVE DISORDER/ or DEPRESSION, POSTPARTUM/ or
	DEPRESSIVE DISORDER, MAJOR/ or DEPRESSIVE DISORDER, TREATMENT-RESISTANT/ or
	DYSTHYMIC DISORDER/ or SEASONAL AFFECTIVE DISORDER/
5	NEUROTIC DISORDERS/
6	DEPRESSION/
7	ADJUSTMENT DISORDERS/
8	ANXIETY DISORDERS/ or AGORAPHOBIA/ or NEUROCIRCULATORY ASTHENIA/ or OBSESSIVE-
	COMPULSIVE DISORDER/ or OBSESSIVE HOARDING/ or PANIC DISORDER/ or PHOBIC
	DISORDERS/ or STRESS DISORDERS, TRAUMATIC/ or COMBAT DISORDERS/ or STRESS
	DISORDERS, POST-TRAUMATIC/ or STRESS DISORDERS, TRAUMATIC, ACUTE/
9	ANXIETY/ or ANXIETY, CASTRATION/ or KORO/
10	ANXIETY, SEPARATION/
11	PANIC/
12	SOMATOFORM DISORDERS/ or BODY DYSMORPHIC DISORDERS/ or CONVERSION
12	DISORDER/ or HYPOCHONDRIASIS/ or NEURASTHENIA/
13	
14	MUNCHAUSEN SYNDROME BY PROXY/ or MUNCHAUSEN SYNDROME/
15 16	FATIGUE SYNDROME, CHRONIC/ OBSESSIVE BEHAVIOR/
10	COMPULSIVE BEHAVIOR/ or BEHAVIOR, ADDICTIVE/
18	IMPULSE CONTROL DISORDERS/ or FIRESETTING BEHAVIOR/ or GAMBLING/ or
10	TRICHOTILLOMANIA/
19	STRESS, PSYCHOLOGICAL/ or BURNOUT, PROFESSIONAL/
20	SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL/ or VAGINISMUS/
21	ANHEDONIA/
22	AFFECTIVE SYMPTOMS/
23	Exp *MENTAL DISORDERS/
24	Exp substance-related disorders/
25	Attention Deficit Disorder with hyperactivity/
26	Exp Autism spectrum disorder/
27	Conduct disorder/
28	Learning disabilities/
29	Intellectual disability/
30	Schizophrenia/ or psychotic disorders/
31	Dementia/
32	(eating disorder* or anorexia nervosa or bulimi* or binge eat*).ti,ab.
33	((self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid*).ti,ab
34	(mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or
	disorder*)) or mania or manic or cyclothymic* or depression or depressive or dysthymi* or
	neurotic or neurosis or adjustment disorder* or antidepress*).ti,ab

35	(anxiety disorder* or agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or
	posttrauma* or post trauma* or combat or somatoform or somati#ation).ti,ab
36	(body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or
50	munchausen or chronic fatigue* or gambling or trichotillomania or vaginismus or
	anhedoni*).ti,ab
37	(affective symptoms or mental disorder* or mental health).ti,ab
57	(anective symptoms of mental disorder ⁺ of mental health).tr,ab
38	(Schizophreni* or psycho* or sever* mental* ill*).ti,ab
39	(alcohol depend* or alcohol* or addict*).ti,ab
40	(drug dependen* or drug abuse* or drug addict*).ti,ab.
41	(Attention deficit hyperactivity disorder* or Attention deficit disorder* or ADHD or conduct
	disorder).ti,ab.
42	(Autis* or autism spectrum disorder or Asperg*).ti,ab
43	(Learning disab* or learning disorder* or intellectual disab*).ti,ab
44	(Dementia or alzheimer*).ti,ab
45	or/1-44
46	(coronavirus OR corona virus OR coronavirinae OR coronaviridae OR betacoronavirus OR
	covid19 OR covid 19 OR nCoV OR CoV 2 OR CoV2 OR sarscov2 OR 2019nCoV OR novel CoV
	OR wuhan virus).ti,ab.
47	((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia) AND
	(outbreak)).ti,ab.
48	Coronavirus/ OR Coronavirus Infections/ OR COVID-19/ OR severe acute respiratory
	syndrome coronavirus 2/ OR Betacoronavirus/
49	OR/46-48
50	Systematic review/ or systematic review.ti,ab,pt
51	Meta-analysis/ or meta-analysis.ti,ab,pt.
52	OR/50-51
53	prevalence/ or morbidity/ or incidence/ or (prevalen* or incidence or morbidity or trend or
	change).ti,ab.
54	AND/45,49,52,53
55	Limit 54 to dt=20191201-20210312
56	Limit 55 to English language

Table A2: OVID EMBASE search strategy

FE 2 Se 3 SU 4 M/ 5 BIF 013 "N 5 DIS 6 DE 9 AD 10 AN 7 PS 8 NE 07 PS 7 PS 8 NE 07 AD 9 AD 10 AN 11 AN 12 OE 13 PH 50 CC 14 SO 15 MC 16 MU	ATING DISORDER/ or ANOREXIA NERVOSA/ or BINGE EATING DISORDER/ or BULIMIA/ or IMALE ATHLETE TRIAD/ or FOOD AVERSION/ or PICA/ If mutilation/ JICIDAL BEHAVIOR/ or SELF POISONING/ or SUICIDAL IDEATION/ or SUICIDE/ or SUICIDE TTEMPT/ ANIA/ or HYPOMANIA/ or MANIC PSYCHOSIS/ POLAR DISORDER/ or BIPOLAR DEPRESSION/ or BIPOLAR I DISORDER/ or BIPOLAR II SORDER/ or BIPOLAR MANIA/ or CYCLOTHYMIA/ or MANIC DEPRESSIVE PSYCHOSIS/ or AIXED MANIA and DEPRESSION' or APID CYCLING BIPOLAR DISORDER/ EPRESSION/ or AGITATED DEPRESSION/ or ATYPICAL DEPRESSION/ or DEPRESSIVE SYCHOSIS/ or DYSPHORIA/ or DYSTHYMIA/ or ENDOGENOUS DEPRESSION/ or VOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION/ or POSTOPERATIVE EPRESSION/ or REMENSTRUAL DYSPHORIC DISORDER/ or PSEUDODEMENTIA/ or JERPERAL DEPRESSION/ or REACTIVE DEPRESSION/ or RECURRENT BRIEF DEPRESSION/ or ASONAL AFFECTIVE DISORDER/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ NEURASTHENIA/ or PSYCHASTHENIA/ DJUSTMENT DISORDER/ EUROSIS/ OR AFFECTIVE NEUROSIS/ OR ANXIETY NEUROSIS/ OR CARDIAC MXIETY/ MXIETY/ DISORDER/ OR ACUTE STRESS DISORDER/ OR ANXIETY NEUROSIS/ OR CARDIAC MXIETY/ OR DISTRESS SYNDROME/ OR GENERALIZED ANXIETY NEUROSIS/ OR CARDIAC MXIETY/ OR DEPRESSION/ OR PANIC/ OR POSTTRAUMATIC STRESS DISORDER/ OR ANXIETY/ OR DEPRESSION/ OR PANIC/ OR POSTTRAUMATIC STRESS DISORDER/ OR ANXIETY/ OR DEPRESSION/ OR PANIC/ OR POSTTRAUMATIC STRESS DISORDER/ OR ANXIETY/ OR DEPRESSION/ OR CAUSTROPHOBIA/ OR HOMOPHOBIA/ OR NEOPHOBIA/ OR DOSTRAUNATIC STRESS ON OR CAUSTROPHOBIA/ OR HOMOPHOBIA/ OR NEOPHOBIA/ OR DOSTRAUPONALSIVE DISORDER/ OR COMPULSION/ OR OBSESSION/ HOBIA/ OR AGORAPHOBIA/ OR CLAUSTROPHOBIA/ OR HOMOPHOBIA/ OR NEOPHOBIA/ OR DOCIAL PHOBIA/
2 Sei 3 SU 4 M/ 5 BIF DIS "N 6 DE 9 AD 10 AN 7 Psv 8 NE 01 AN 10 AN 11 AN 12 OE 13 PH 50 14 15 MC 16 MI	If mutilation/ JICIDAL BEHAVIOR/ or SELF POISONING/ or SUICIDAL IDEATION/ or SUICIDE/ or SUICIDE TTEMPT/ ANIA/ or HYPOMANIA/ or MANIC PSYCHOSIS/ POLAR DISORDER/ or BIPOLAR DEPRESSION/ or BIPOLAR I DISORDER/ or BIPOLAR II SORDER/ or BIPOLAR MANIA/ or CYCLOTHYMIA/ or MANIC DEPRESSIVE PSYCHOSIS/ or AIXED MANIA and DEPRESSION'' or RAPID CYCLING BIPOLAR DISORDER/ EPRESSION/ or AGITATED DEPRESSION/ or ATYPICAL DEPRESSION/ or DEPRESSIVE SYCHOSIS/ or DYSPHORIA/ or DYSTHYMIA/ or ENDOGENOUS DEPRESSION/ or VOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION' or "MIXED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION' or RECURRENTIA'/ or JERPERAL DEPRESSION/ or REACTIVE DEPRESSION/ or RECURRENT BRIEF DEPRESSION/ or ASSONAL AFFECTIVE DISORDER/ ychotic disorders/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ NEURASTHENIA/ or PSYCHASTHENIA/ DJUSTMENT DISORDERS/ NXIETY/ NXIETY DISORDERS/ OR ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC NXIETY/ OF DISTRESS SYNDROME/ OR GENERALIZED ANXIETY NEUROSIS/ OR CARDIAC NXIETY/ DISORDERS/ OR ACUTE STRESS DISORDER/ OR ANXIETY NEUROSIS/ OR CARDIAC NXIETY AND DEPRESSION'/ OR GENERALIZED ANXIETY NEUROSIS/ OR CARDIAC NXIETY/ OF DISTRESS SYNDROME/ OR GENERALIZED ANXIETY DISORDER/ OR KORO/ OR AIXED ANXIETY and DEPRESSION'/ OR POSTTRAUMATIC STRESS DISORDER/ OR YCHASTHENIA/ OR SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ OR COMPULSION/ OR OBSESSION/ HOBIA/ OR AGORAPHOBIA/ OR CLAUSTROPHOBIA/ OR HOMOPHOBIA/ OR NEOPHOBIA/ OR
3 SU AT 4 M/ 5 BIF DIS "N 6 DE PS IN ME 6 DE PS IN ME 7 PS S 7 PS S 7 PS S 8 NE OT 9 AD 10 AN 11 AN PS' 12 13 PH SO 14 SO 15 MC 16 MI	JICIDAL BEHAVIOR/ or SELF POISONING/ or SUICIDAL IDEATION/ or SUICIDE/ or SUICIDE TTEMPT/ ANIA/ or HYPOMANIA/ or MANIC PSYCHOSIS/ POLAR DISORDER/ or BIPOLAR DEPRESSION/ or BIPOLAR I DISORDER/ or BIPOLAR II SORDER/ or BIPOLAR MANIA/ or CYCLOTHYMIA/ or MANIC DEPRESSIVE PSYCHOSIS/ or MIXED MANIA and DEPRESSION' or RAPID CYCLING BIPOLAR DISORDER/ EPRESSION/ or AGITATED DEPRESSION/ or ATYPICAL DEPRESSION/ or DEPRESSIVE SYCHOSIS/ or DYSPHORIA/ or DYSTHYMIA/ or ENDOGENOUS DEPRESSION/ or VOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION/ or POSTOPERATIVE EPRESSION/ or PREMENSTRUAL DYSPHORIC DISORDER/ or PSEUDODEMENTIA/ or JERPERAL DEPRESSION/ or REACTIVE DEPRESSION/ or RECURRENT BRIEF DEPRESSION/ or ASONAL AFFECTIVE DISORDER/ Sychotic disorders/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ NEURASTHENIA/ or PSYCHASTHENIA/ DJUSTMENT DISORDERS/ NXIETY/ NXIETY DISORDER/ or ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY NEUROSIS/ or CARDIAC NXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or SYCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or CAMPULSION/ or OBSESSION/ HOBIA/ OR AGORAPHOBIA/ OR CLAUSTROPHOBIA/ OR HOMOPHOBIA/ OR NEOPHOBIA/ OR
4 M/ 4 M/ 5 BIF DIS N/ 6 DE PS IN/ 6 DE PS IN/ 0 DE PU SE 7 PS/ 8 NE 01 AN 10 AN 11 AN 12 OE 13 PH SO IA 14 SO 15 M(0) 16 M(1)	TTEMPT/ ANIA/ or HYPOMANIA/ or MANIC PSYCHOSIS/ POLAR DISORDER/ or BIPOLAR DEPRESSION/ or BIPOLAR I DISORDER/ or BIPOLAR II SORDER/ or BIPOLAR MANIA/ or CYCLOTHYMIA/ or MANIC DEPRESSIVE PSYCHOSIS/ or AIXED MANIA and DEPRESSION"/ or RAPID CYCLING BIPOLAR DISORDER/ EPRESSION/ or AGITATED DEPRESSION/ or ATYPICAL DEPRESSION/ or DEPRESSIVE SYCHOSIS/ or DYSPHORIA/ or DYSTHYMIA/ or ENDOGENOUS DEPRESSION/ or VOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION"/ or "MIXED DEPRESSION AND EMENTIA"/ or MOURNING SYNDROME/ or ORGANIC DEPRESSION/ or POSTOPERATIVE EPRESSION/ or PREMENSTRUAL DYSPHORIC DISORDER/ or PSEUDODEMENTIA/ or JERPERAL DEPRESSION/ or REACTIVE DEPRESSION/ or RECURRENT BRIEF DEPRESSION/ or ASSONAL AFFECTIVE DISORDER/ cychotic disorders/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ NEURASTHENIA/ or PSYCHASTHENIA/ DJUSTMENT DISORDERS/ NXIETY/ NXIETY/ NXIETY/ NXIETY DISORDERS/ or ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY DISORDER/ or KORO/ or AIXED ANXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or YCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ 40BIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
5 BIF DIS "N 6 DE PS IN MI DE DE DE PU SE 7 7 PS 0 7 PS 0 7 PS 0 7 PS 0 10 AN 0 11 AN 0 12 OE 13 13 PH SO 14 SO CC 15 MC 16 MI	POLAR DISORDER/ or BIPOLAR DEPRESSION/ or BIPOLAR I DISORDER/ or BIPOLAR II SORDER/ or BIPOLAR MANIA/ or CYCLOTHYMIA/ or MANIC DEPRESSIVE PSYCHOSIS/ or MIXED MANIA and DEPRESSION"/ or RAPID CYCLING BIPOLAR DISORDER/ EPRESSION/ or AGITATED DEPRESSION/ or ATYPICAL DEPRESSION/ or DEPRESSIVE SYCHOSIS/ or DYSPHORIA/ or DYSTHYMIA/ or ENDOGENOUS DEPRESSION/ or VOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION"/ or "MIXED DEPRESSION AND EMENTIA"/ or MOURNING SYNDROME/ or ORGANIC DEPRESSION/ or POSTOPERATIVE EPRESSION/ or PREMENSTRUAL DYSPHORIC DISORDER/ or PSEUDODEMENTIA/ or JERPERAL DEPRESSION/ or REACTIVE DEPRESSION/ or RECURRENT BRIEF DEPRESSION/ or ASSONAL AFFECTIVE DISORDER/ wychotic disorders/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ 'NEURASTHENIA/ or PSYCHASTHENIA/ DJUSTMENT DISORDERS/ WXIETY/ WXIETY/ WXIETY/ OR DISORDERS/ OR GENERALIZED ANXIETY NEUROSIS/ or CARDIAC WXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or AIXED ANXIETY and DEPRESSION"/ or PANIC/ or OSTTRAUMATIC STRESS DISORDER/ or YCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ OR AGORAPHOBIA/ OR CLAUSTROPHOBIA/ OR HOMOPHOBIA/ OR NEOPHOBIA/ OR
DIS "N 6 DE PS' INN DE PS' INN DE DE PU SE 7 PS' 8 01 10 AN 11 AN IN PS' 12 OE 13 PH SO 14 SO 15 MC AF 16 MI	SORDER/ or BIPOLAR MANIA/ or CYCLOTHYMIA/ or MANIC DEPRESSIVE PSYCHOSIS/ or MIXED MANIA and DEPRESSION'/ or RAPID CYCLING BIPOLAR DISORDER/ EPRESSION/ or AGITATED DEPRESSION/ or ATYPICAL DEPRESSION/ or DEPRESSIVE SYCHOSIS/ or DYSPHORIA/ or DYSTHYMIA/ or ENDOGENOUS DEPRESSION/ or VOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION"/ or "MIXED DEPRESSION AND EMENTIA"/ or MOURNING SYNDROME/ or ORGANIC DEPRESSION/ or POSTOPERATIVE EPRESSION/ or PREMENSTRUAL DYSPHORIC DISORDER/ or PSEUDODEMENTIA/ or JERPERAL DEPRESSION/ or REACTIVE DEPRESSION/ or RECURRENT BRIEF DEPRESSION/ or ASONAL AFFECTIVE DISORDER/ wychotic disorders/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ NEURASTHENIA/ or PSYCHASTHENIA/ DJUSTMENT DISORDERS/ WXIETY/ WXIETY/ WXIETY DISORDER/ or ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC WXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or YCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ OR AGORAPHOBIA/ OR CLAUSTROPHOBIA/ OR HOMOPHOBIA/ OR NEOPHOBIA/ OR
PS INV MH DE PU SE 7 PS 8 0r 9 AD 10 AN IN PS 10 AN PS 12 OE 13 PH SO 14 SO 15 MC AF 16	SYCHOSIS/ or DYSPHORIA/ or DYSTHYMIA/ or ENDOGENOUS DEPRESSION/ or VOLUTIONAL DEPRESSION/ or MAJOR DEPRESSION/ or MASKED DEPRESSION/ or ELANCHOLIA/ or "MIXED ANXIETY and DEPRESSION/ or "MIXED DEPRESSION AND EMENTIA"/ or MOURNING SYNDROME/ or ORGANIC DEPRESSION/ or POSTOPERATIVE EPRESSION/ or PREMENSTRUAL DYSPHORIC DISORDER/ or PSEUDODEMENTIA/ or JERPERAL DEPRESSION/ or REACTIVE DEPRESSION/ or RECURRENT BRIEF DEPRESSION/ or ASONAL AFFECTIVE DISORDER/ cychotic disorders/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ NEURASTHENIA/ or PSYCHASTHENIA/ DUSTMENT DISORDERS/ NXIETY/ NXIETY/ NXIETY/ ON DISTRESS SYNDROME/ or GENERALIZED ANXIETY NEUROSIS/ or CARDIAC NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY DISORDER/ or KORO/ or AIXED ANXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or SYCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
8 NE or 9 AD 10 AN 11 AN AN "N PS 12 OE 13 PH SO 14 SO CC DE 15 MC AF 16 MI	EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ EUROSIS/ or AFFECTIVE NEUROSIS/ or ANXIETY NEUROSIS/ or DYSTHYMIA/ or HYSTERIA/ DJUSTMENT DISORDERS/ NXIETY/ NXIETY/ NXIETY DISORDER/ or ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY DISORDER/ or KORO/ or AIXED ANXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or SYCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
or 9 AD 10 AN 11 AN 11 AN 12 OB 13 PH 50 CC 14 SO 15 MC 16 MI	NEURASTHENIA/ or PSYCHASTHENIA/ DJUSTMENT DISORDERS/ NXIETY/ NXIETY/ DISORDER/ or ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY DISORDER/ or KORO/ or AIXED ANXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or SYCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
10 AN 11 AN 11 AN AN "N PS PS 12 OE 13 PH SO CC 14 SO 15 MC AF 16	NXIETY/ NXIETY DISORDER/ or ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY DISORDER/ or KORO/ or AIXED ANXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or SYCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
11 AN AN "N PS' DE 12 OE 13 PH SO CC 14 SO 15 MC AF AF 16 MI	NXIETY DISORDER/ or ACUTE STRESS DISORDER/ or ANXIETY NEUROSIS/ or CARDIAC NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY DISORDER/ or KORO/ or AIXED ANXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or SYCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
AN "W PS" 12 OE 13 PH 50 14 SO CC DE 14 SO CC DE 15 M(AF 16 M(NXIETY/ or DISTRESS SYNDROME/ or GENERALIZED ANXIETY DISORDER/ or KORO/ or /IXED ANXIETY and DEPRESSION"/ or PANIC/ or POSTTRAUMATIC STRESS DISORDER/ or SYCHASTHENIA/ or SEPARATION ANXIETY/ BSESSIVE COMPULSIVE DISORDER/ or COMPULSION/ or OBSESSION/ HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
13 PH SO 14 SO CC DE 15 M0 AF 16 M0	HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
13 PH SO 14 SO CC DE 15 M0 AF 16 M0	HOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or HOMOPHOBIA/ or NEOPHOBIA/ or
14 SO CC DE 15 MC AF 16 MI	
15 M AF 16 M	DMATOFORM DISORDER/ or BODY DYSMORPHIC DISORDER/ or CARDIAC ANXIETY/ or DNVERSION DISORDER/ or DELUSIONAL PREGNANCY/ or HYPOCHONDRIASIS/ or MASKED EPRESSION/ or PSYCHOGENIC PAIN/ or SOMATIC DELUSION/ or SOMATIZATION/
	OOD DISORDER/ or AFFECTIVE NEUROSIS/ or AFFECTIVE PSYCHOSIS/ or BLUNTED FECT/ or MAJOR AFFECTIVE DISORDER/ or MINOR AFFECTIVE DISORDER/
47	UNCHAUSEN SYNDROME BY PROXY/ or MUNCHAUSEN SYNDROME/
KO PS	SYCHOSEXUAL DISORDER/ or ANORGASMIA/ or CASTRATION ANXIETY/ or FRIGIDITY/ or DRO/ or LIBIDO DISORDER/ or OEDIPUS COMPLEX/ or ORGASM DISORDER/ or SYCHOGENIC IMPOTENCE/ or SEXUAL ADDICTION/ or SEXUAL AROUSAL DISORDER/ or AGINISM/
	1PULSE CONTROL DISORDER/ or INTERMITTENT EXPLOSIVE DISORDER/ or KLEPTOMANIA/ PATHOLOGICAL GAMBLING/ or PYROMANIA/ or TRICHOTILLOMANIA/
	ental stress/ or emotional disorder/
20 Scl	hizophrenia/ or psychosis/ or (schizophren* or psycho* or severe* mental* ill*).ti,ab
	p drug dependence/
22 Att	tention deficit disorder/
23 Au	utism/
24 Co	
25 Lea	onduct disorder/
26 Int	onduct disorder/ earning disorder/

27	Dementia/
28	eating disorder* or anorexia nervosa or bulimi* or binge eat*.ti,ab.
29	((self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid*).ti,ab
30	(mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or
50	disorder*)) or mania or manic or cyclothymic* or depression or depressive or dysthymi* or
	neurotic or neurosis or adjustment disorder* or antidepress*).ti,ab
31	(anxiety disorder* or agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or
	posttrauma* or post trauma* or combat or somatoform or somati#ation).ti,ab
32	(body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or
	munchausen or chronic fatigue* or gambling or trichotillomania or vaginismus or
	anhedoni*).ti,ab
33	(affective symptoms or mental disorder* or mental health).ti,ab
34	(alcohol dependen* or alcohol* or addict*).ti,ab
35	(drug dependen* or drug abuse* or addict*)).ti,ab
36	(Attention deficit hyperactivity disorder* or Attention deficit disorder* or ADHD or conduct
	disorder).ti,ab.
37	(Autis* or autism spectrum disorder or Asperg*).ti,ab
38	(Learning disab* or learning disorder* or intellectual disab*).ti,ab
39	(Dementia or alzheimer*).ti,ab
40	or/1-39
41	(coronavirus OR corona virus OR coronavirinae OR coronaviridae OR betacoronavirus OR
	covid19 OR covid 19 OR nCoV OR CoV 2 OR CoV2 OR sarscov2 OR 2019nCoV OR novel
	CoV OR wuhan virus).ti,ab.
42	((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia) AND
	(outbreak)).ti,ab.
43	Coronavirinae/ OR Coronavirus Infection/ OR Betacoronavirus/ OR severe acute
	respiratory infection/
44 45	OR/41-43
45	Systematic review/ or systematic review.ti,ab,pt. Meta analysis/ or meta-analysis.ti,ab,pt.
	OR/45-46
47 48	prevalence/ or morbidity/ or incidence/ or (prevalen* or incidence or morbidity or trend or
40	change).ti,ab.
49	AND/40,44,47,48
50	Limit 49 to dd=20191201-20210312
-	
51	Limit 50 to English language

Table A3: OVID PsycInfo search strategy

1	
1	EATING DISORDERS/ or ANOREXIA NERVOSA/ or BULIMIA/ or HYPERPHAGIA/ or KLEINE
2	LEVIN SYNDROME/ or PICA/ or "PURGING (EATING DISORDERS)"/
2	APHAGIA/
3	COPROPHAGIA/
4	BINGE EATING/
5	SELF DESTRUCTIVE BEHAVIOR/ or ATTEMPTED SUICIDE/ or HEAD BANGING/ or SELF
	INFLICTED WOUNDS/ or SELF INJURIOUS BEHAVIOR/ or SELF MUTILATION/ or SUICIDE/
6	SUICIDE PREVENTION/
7	SUICIDAL IDEATION/
8	AFFECTIVE DISORDERS/
9	AFFECTIVE PSYCHOSIS/
10	BIPOLAR DISORDER/ or CYCLOTHYMIC PERSONALITY/
11	MAJOR DEPRESSION/ or ANACLITIC DEPRESSION/ or DYSTHYMIC DISORDER/ or
	ENDOGENOUS DEPRESSION/ or POSTPARTUM DEPRESSION/ or REACTIVE DEPRESSION/ or
	RECURRENT DEPRESSION/ or TREATMENT RESISTANT DEPRESSION/
12	ATYPICAL DEPRESSION/
13	"DEPRESSION (EMOTION)"/
14	SEASONAL AFFECTIVE DISORDER/
15	ANXIETY DISORDERS/ or ACUTE STRESS DISORDER/ or CASTRATION ANXIETY/ or DEATH
	ANXIETY/ or GENERALIZED ANXIETY DISORDER/ or OBSESSIVE COMPULSIVE DISORDER/ or
	PANIC DISORDER/ or POSTTRAUMATIC STRESS DISORDER/ or SEPARATION ANXIETY/
16	PHOBIAS/ or ACROPHOBIA/ or AGORAPHOBIA/ or CLAUSTROPHOBIA/ or OPHIDIOPHOBIA/
	or SCHOOL PHOBIA/ or SOCIAL PHOBIA/
17	"DEBRIEFING (PSYCHOLOGICAL)"/
18	NEUROSIS/ or CHILDHOOD NEUROSIS/ or EXPERIMENTAL NEUROSIS/ or OCCUPATIONAL
	NEUROSIS/ or TRAUMATIC NEUROSIS/
19	ADJUSTMENT DISORDERS/
20	COPING BEHAVIOR/
21	ADJUSTMENT/ or EXP EMOTIONAL ADJUSTMENT/ or OCCUPATIONAL ADJUSTMENT/ or
	SCHOOL ADJUSTMENT/ or SOCIAL ADJUSTMENT/
22	EMOTIONAL TRAUMA/
23	STRESS/ or CHRONIC STRESS/ or ENVIRONMENTAL STRESS/ or OCCUPATIONAL STRESS/ or
	PSYCHOLOGICAL STRESS/ or SOCIAL STRESS/ or STRESS REACTIONS/
24	ANXIETY/ or COMPUTER ANXIETY/ or MATHEMATICS ANXIETY/ or PERFORMANCE ANXIETY/
	or SOCIAL ANXIETY/ or SPEECH ANXIETY/ or TEST ANXIETY/
25	PANIC ATTACK/ or PANIC/ or PANIC DISORDER/
26	SOMATOFORM DISORDERS/ or BODY DYSMORPHIC DISORDER/ or HYPOCHONDRIASIS/ or
	NEURASTHENIA/ or NEURODERMATITIS/ or SOMATIZATION DISORDER/ or SOMATOFORM
	PAIN DISORDER/
27	CONVERSION DISORDER/ or HYSTERICAL PARALYSIS/ or HYSTERICAL VISION
	DISTURBANCES/ or PSEUDOCYESIS/
28	SOMATIZATION/
20	

29	HYSTERIA/ OR MASS HYSTERIA/
30	HYSTERICAL PARALYSIS/
31	HISTRIONIC PERSONALITY DISORDER/
32	MALINGERING/
33	FACTITIOUS DISORDERS/ or MUNCHAUSEN SYNDROME BY PROXY/ or MUNCHAUSEN
	SYNDROME/
34	CHRONIC FATIGUE SYNDROME/
35	COMPULSIONS/ OR REPETITION COMPULSION/
36	OBSESSIONS/
37	OBSESSIVE COMPULSIVE PERSONALITY DISORDER/
38	TRICHOTILLOMANIA/
39	GAMBLING/ or PATHOLOGICAL GAMBLING/
40	SEXUAL FUNCTION DISTURBANCES/ or DYSPAREUNIA/ or ERECTILE DYSFUNCTION/ or
	FEMALE SEXUAL DYSFUNCTION/ or INHIBITED SEXUAL DESIRE/ or PREMATURE
	EJACULATION/ or VAGINISMUS/
41	PREMENSTRUAL DYSPHORIC DISORDER/
42	*MENTAL DISORDERS/
43	Psychosis/ or schizophrenia/
44	Alcoholism/ or alcohol abuse/ or "substance use disorder"/
45	Attention deficit disorder with hyperactivity/
46	Autism spectrum disorders/
47	Conduct disorder/
48	Learning disabilities/
49	Intellectual development disorder/
50	Dementia/
51	(eating disorder* or anorexi* or bulimi* or binge eat*).ti,ab
52	(self adj (injur* or mutilat*) or suicide* or suicidal or parasuicid*).ti,ab
53	(mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or
	disorder*)) or mania or manic or cyclothymi* or depression or depressive or
	dysthymi*).ti,ab
54	(neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or
	agoraphobia).ti,ab.
55	(obsess* or compulsi* or panic or phobi*).ti,ab
56	(ptsd or posttrauma* or post trauma* or combat).ti,ab
57	(somatoform or somati#ation or medical* unexplained or body dysmorphi* or conversion
	disorder or hypochondria* or neurastheni*).ti,ab.
58	(hysteria or munchausen or chronic fatigue* or gambling or trichotillomania or vaginismus
	or anhedoni* or affective symptoms or mental disorder* or mental health).ti,ab.
59	(alcohol depend* or alcohol* or addict*).ti,ab
60	(drug depend* or drug abuse* or drug addict*).ti,ab
61	(Attention deficit hyperactivity disorder* or Attention deficit disorder* or ADHD or conduct
	disorder).ti,ab.
62	(Autis* or autism spectrum disorder or Asperg*).ti,ab
63	(Learning disab* or learning disorder* or intellectual disab*).ti,ab

64	(Dementia or alzheimer*).ti,ab
65	or/1-64
66	(coronavirus OR corona virus OR coronavirinae OR coronaviridae OR betacoronavirus OR
	covid19 OR covid 19 OR nCoV OR CoV 2 OR CoV2 OR sarscov2 OR 2019nCoV OR novel CoV
	OR wuhan virus).ti,ab.
67	((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia) AND
	(outbreak)).ti,ab.
68	Coronavirus/ OR severe acute respiratory syndrome/
69	OR/66-68
70	Systematic review/ or systematic review.ti,ab,pt. Or review.ti,ab
71	Meta-analysis/ or meta-analysis.ti,ab,pt
72	OR/70-71
73	epidemiology/ or morbidity/ or (prevalen* or incidence or morbidity or trend or
	change).ti,ab.
74	AND/65,69,72,73
75	Limit 74 to up=20191201-20210312
76	Limit 75 to English language

Table A4: CINAHL search strategy

4	
1	MH EATING DISORDERS OF MH ANOREXIA NERVOSA OF MH BINGE EATING DISORDER OF MH
2	BULIMIA NERVOSA or MH FEMALE ATHLETE TRIAD or MH PICA
2	MH HYPERPHAGIA
3	MH SELF-INJURIOUS BEHAVIOR or MH SUICIDE or MH SUICIDAL IDEATION or MH SUICIDE,
	ATTEMPTED
4	MH AFFECTIVE DISORDERS, MH PSYCHOTIC or MH BIPOLAR DISORDER or MH
	CYCLOTHYMIC DISORDER or MH DEPRESSION, POSTPARTUM or MH DYSTHYMIC DISORDER
	or MH SEASONAL AFFECTIVE DISORDER
5	MH NEUROTIC DISORDERS
6	MH DEPRESSION
7	MH ADJUSTMENT DISORDERS
8	MH ANXIETY DISORDERS or MH AGORAPHOBIA or MH ASTHENIA or MH OBSESSIVE-
	COMPULSIVE DISORDER or MH OBSESSIVE HOARDING or MH PANIC DISORDER or MH
	PHOBIC DISORDERS or MH STRESS DISORDERS, POST-TRAUMATIC
9	MH ANXIETY
10	MH SEPARATION ANXIETY
11	MH SOMATOFORM DISORDERS or MH BODY DYSMORPHIC DISORDER or MH
	HYPOCHONDRIASIS
12	MH HYSTERIA
13	MH MUNCHAUSEN SYNDROME BY PROXY or MH MUNCHAUSEN SYNDROME
14	MH FATIGUE SYNDROME, CHRONIC
15	MH COMPULSIVE BEHAVIOR or MH BEHAVIOR, ADDICTIVE
16	MH IMPULSE CONTROL DISORDERS or MH GAMBLING or MH TRICHOTILLOMANIA
17	MH STRESS, PSYCHOLOGICAL or MH BURNOUT, PROFESSIONAL
18	MH PSYCHOSEXUAL DISORDERS
19	MH ANHEDONIA
20	MH AFFECTIVE SYMPTOMS
21	MH MENTAL DISORDERS+
22	MH substance USE disorders+
23	MH Attention Deficit hyperactivity disorder
24	MH AUTISTIC DISORDER or MH ASPERGER SYNDROME
25	MH Learning disorders
26	MH Intellectual disability
27	MH Schizophrenia or MH psychotic disorders
28	MH Dementia
29	("eating disorder*" or "anorexia nervosa" or bulimi* or "binge eat*")
30	((self w1 (injur* or mutilat*)) or suicide* or suicidal or parasuicid*)
31	("mood disorder*" or "affective disorder*" or "bipolar I" or "bipolar ii" or (bipolar and
	(affective or disorder*)) or mania or manic or cyclothymic* or depression or depressive or
	dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress*)
32	("anxiety disorder*" or agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or
52	posttrauma* or "post trauma*" or combat or somatoform or somati#ation)
33	("body dysmorphi*" or "conversion disorder" or hypochondria* or neurastheni* or hysteria
	or munchausen or chronic fatigue* or gambling or trichotillomania or vaginismus or
	anhedoni*)
34	("affective symptoms" or "mental disorder*" or "mental health")

35	Schizophreni* or psycho* or "sever* mental* ill*"
36	"alcohol depend*" or alcohol* or addict*
37	"drug dependen*" or "drug abuse*" or "drug addict*"
38	"Attention deficit hyperactivity disorder*" or "Attention deficit disorder*" or ADHD or
	"conduct disorder"
39	Autis* or "autism spectrum disorder" or Asperg*
40	"Learning disab*" or "learning disorder*" or "intellectual disab*"
41	Dementia or alzheimer*
42	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR
	S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR
	S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR
	S38 OR S39 OR S40 OR S41
43	coronavirus OR "corona virus" OR coronavirinae OR coronaviridae OR betacoronavirus OR
	covid19 OR "covid 19" OR nCoV OR "CoV 2" OR CoV2 OR sarscov2 OR 2019nCoV OR novel
	CoV OR "wuhan virus"
44	(wuhan OR hubei OR huanan) AND ("severe acute respiratory" OR pneumonia) AND
	(outbreak)
45	MH Coronavirus OR MH Coronavirus Infections OR MH COVID-19
46	S43 OR S44 OR S45
47	MH Systematic review or "systematic review" or "rapid review" or "umbrella review"
48	MH Meta-analysis or meta-analysis
49	S47 OR S48
50	S42 AND S46 AND S49
51	EM 20191201-20210312
52	S50 AND S51

Table A5: COCHRANE library search strategy

1	MeSH descriptor EATING DISORDERS explode all trees
2	MeSH descriptor BULIMIA this term only
3	MeSH descriptor SELF-INJURIOUS BEHAVIOR this term only
4	MeSH descriptor SELF MUTILATION this term only
5	MeSH descriptor SUICIDE this term only
6	Mesh descriptor SUICIDE, ATTEMPTED this term only
7	Mesh descriptor SUICIDAL IDEATION this term only
8	MeSH descriptor MOOD DISORDERS explode all trees
9	Mesh descriptor NEUROTIC DISORDERS this term only
10	MeSH descriptor DEPRESSION this term only
11	MeSH descriptor ADJUSTMENT DISORDERS this term only
12	MeSH descriptor ANXIETY this term only
13	MeSH descriptor ANXIETY, CASTRATION explode all trees
14	MeSH descriptor ANXIETY DISORDERS explode all trees
15	MeSH descriptor ANXIETY, SEPARATION this term only
16	MeSH descriptor PANIC this term only
17	MeSH descriptor SOMATOFORM DISORDERS explode all trees
18	MeSH descriptor HYSTERIA this term only
19	MeSH descriptor FACTITIOUS DISORDERS explode all trees
20	MeSH descriptor FATIGUE SYNDROME, CHRONIC this term only
21	MeSH descriptor OBSESSIVE BEHAVIOR explode all trees
22	MeSH descriptor COMPULSIVE BEHAVIOR explode all trees
23	MeSH descriptor GAMBLING this term only
24	MeSH descriptor TRICHOTILLOMANIA this term only
25	MeSH descriptor SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL this term only
26	MeSH descriptor DYSPAREUNIA this term only
27	MeSH descriptor VAGINISMUS this term only
28	MeSH descriptor STRESS, PSYCHOLOGICAL explode all trees
29	MeSH descriptor AFFECTIVE SYMPTOMS this term only
30	anorexia and nervosa
31	bulimi*
32	eating and disorder*
33	suicid* or parasuicid*
34	self and mutilat*
35	self and injur*
36	affective and disorder*
37	mood and disorder*
38	bipolar
39	mania or manic or hypomani*
40	((rapid NEXT cycling) and disorder*)
41	schizoaffective
42	neurotic or neurosis or neuroses or psychoneuro*
43	depress*
44	dysthymi* anxiety or anxious
45	
43 47	panic (phobia* or phobic* or agoraphobi* or clasutrophobi* or acrophobi* or ophidiophobi*)

48	stress and disorder*						
49	(PTSD or posttrauma* or post-trauma* or (post NEXT trauma*))						
50	psychological and stress*						
51	combat						
52	somatoform or somatic or somatization						
53	hypochondri*						
54	hysteri*						
55	conversion and disorder*						
56	neurastheni*						
57	munchausen						
58	(chronic and fatigue and syndrome) or CFS						
59	OCD or obsess* or compulsi*						
60	(gambl* or betting or wagering or ludomania* or ludopath*)						
61	trichotillomani*						
62	Mesh descriptor: [substance-related disorders] 1 tree(s) exploded						
63	Mesh descriptor: [Attention Deficit Disorder with hyperactivity]						
64	Mesh descriptor: [Autism spectrum disorder]						
65	Mesh descriptor: [Conduct disorder]						
66	Mesh descriptor: [Learning disabilities]						
67	Mesh descriptor: [Intellectual disability]						
68	Mesh descriptor: [schizophrenia spectrum and other psychotic disorder]						
69	Mesh descriptor: [Dementia]						
70	(eating disorder* or anorexia nervosa or bulimi* or binge eat*):ti,ab						
71	((self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid*):ti,ab						
72	(mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or						
	disorder*)) or mania or manic or cyclothymic* or depression or depressive or dysthymi* or						
	neurotic or neurosis or adjustment disorder* or antidepress*):ti,ab						
73	(anxiety disorder* or agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or						
	posttrauma* or post trauma* or combat or somatoform or somati#ation):ti,ab						
74	(body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or						
	munchausen or chronic fatigue* or gambling or trichotillomania or vaginismus or						
	anhedoni*):ti,ab						
75	(affective symptoms or mental disorder* or mental health):ti,ab						
76	(Schizophreni* or psycho* or sever* mental* ill*):ti,ab						
77	(alcohol depend* or alcohol* or addict*):ti,ab						
78	(drug dependen* or drug abuse* or drug addict*):ti,ab.						
79	(Attention deficit hyperactivity disorder* or Attention deficit disorder* or ADHD or conduct disorder):ti,ab.						
80	(Autis* or autism spectrum disorder or Asperg*):ti,ab						
81	(Learning disab* or learning disorder* or intellectual disab*):ti,ab						
82	(Dementia or alzheimer*):ti,ab						
83	Or 1-82						
84	(coronavirus OR corona virus OR coronavirinae OR coronaviridae OR betacoronavirus OR						
04	covid19 OR covid 19 OR nCoV OR CoV 2 OR CoV2 OR sarscov2 OR 2019nCoV OR novel CoV						
	OR wuhan virus):ti,ab.						
85	((wuhan OR hubei OR huanan) AND (severe acute respiratory OR pneumonia) AND						
0.5	(outbreak)):ti,ab.						
	נטמנטו <i>כמהון.</i> נו,מט.						

86	Mesh descriptor: [Coronavirus]					
87	Mesh descriptor: [Coronavirus Infections]					
88	MeSh descriptor: [COVID-19]					
89	MeSH descriptor: [SARS-CoV-2]					
90	Mesh descriptor: [Betacoronavirus]					
91	OR/84-90					
92	Mesh descriptor: [Systematic review]					
93	systematic review					
94	Mesh descriptor: [Meta-analysis]					
95	or meta-analysis.ti,ab,pt.					
96	OR/92-95					
98	AND/83,91,96					

Table A6: Characteristics of included systematic reviews.

Study ID	Search dates	Databases searched	Inclusion/exclusion	Number of studies included	Country where studies took place (N)	Study design included (N studies)	N participants included (% Female)	Population (N studies)
	Database inception until 12-	PsychInfo (Ovid), MEDLINE (Ovid), Embase (Ovid), CINAHL (Ebsco), Scopus, Web	Published peer-reviewed journal articles were included if they met the following criteria: (1) were published in either French or English, (2) had empirical data on the prevalence of mental health symptoms or disorders collected during the COVID-19 pandemic. There were no restrictions in terms of age or the type of population studied (e.g., HCW,		China (44), Italy (4), India and Singapore (1), France (1), United States (1), Iran (5), Vietnam (1), Spain (1), Turkey (1), Israel (1), Singapore (1), Bolivia (1), Ecuador (1), Malaysia (1), Multiple countries (2),			General population (41), Healthcare
Cenat et al., 2020	05-2020	of Science	patients, non-patients).	55	Pakistan (1), Peru (1)	NR	189,159	Workers (27)

Castaldelli-Maia et al., 2020	Database inception until 29- 07-2020	MEDLINE, Web od Science, BIOSIS Citation Index, Current Connect, PsychInfo, CINAHL Pubmed, Scopus, Embase, PsycINFO, Cochrane Library, Web	We included studies that reported categorical assessment of anxiety and depression using GAD-7 and PHQ-9 scales during the COVID-19 pandemic. Randomized controlled trials, cohort studies, case-control studies, and cross- sectional studies were included. Pre-prints and letters were included if they described original research. Inclusion: (a) studies had to report data on mental health indexes linked to epidemic infections, which required containment interventions based on quarantine; (b) only those studies were included in which valid and reliable instruments were administered, which reported the cut-off value of clinical relevance, to assess mental health impacts of quarantine; (c) studies had to be written in English.		India (2), Korea (1), Iran (1), Saudi Arabia (2), Italy (2), Russia (1), Germany (2), China (23), United States (4), United Kingdom (2), Bangladesh (1), Norway (1), Albania (1), Spain (1), Jordan (1), Vietnam (1), Nigeria (1), Austria (1), United Arab Emerites (2), Pakistan (2), Brazil (1), Nepal (1), Cyprus (1), Japan (2), Serbia (1), Switzerland (1).	226,638 (61.9%)	General population (27), Healthcare providers (16), mixed (7), students (11), patients (6)
Cavicchioli et al., 2021	July 2020	of Science	Exclusion: Case reports,	21	United States, Korea,		

Incept - 05-07 Hessami et al., 2020 2020	Inclusion: a study with an observational design in the English language evaluated the depression and anxiety among the studied population using Edinburgh Postnatal Depression Scale (EPDS) and State-Trait Anxiety Inventory (STAI) scores respectively. Exclusion: Other records such as case report, animal study, letter to editor, review study, abstracts without full text were excluded.	8	Italy (2), Chnia (1), Canada (3), Turkey (1), Greece (1)	Case-control (1), cross- sectional (5), prosopective observational (1), not reported (1)	7750 (100%)	Pregnant or postpartum women

1			Inducion (1) muhliched					
			Inclusion: (1) published					
			in English or Chinese					
			since the outbreak of					
			COVID-19 in December					
			2019; (2) report on					
			depression, anxiety or					
			PTSD among health care					
			workers (both clinical					
			and support) in a country					
			affected by COVID-19; (3)					
			used an established					
			assessment of					
			depression, anxiety or			All cross-		
			PTSD, through either a			sectional,		
			self-report			Five studies		
			screening tool or			adopted		
			diagnostic interview; (4)			random		
			provided sufficient			sampling		
			information to calculate			techniques,		
			prevalence of			whilst the		
			depression, anxiety or			other 60 used		
			PTSD among health care			non-random		
			workers (e.g. percentage			methods (for		
			or sample size and			example, self-		
			number).			selection		
		Embase,			Italy (3), Thailand (1),	through		
		MEDLINE,			Oman (1), Chnia (43),	an online		
		PsychINFO,	Exclusion: qualitative		India (2), Singapore and	survey, or		
		Global Health,	studies, study protocols		India (1), United Kingdom	purposeful		
		Web of	and review articles. We		(1), China and Hong Kong	sampling).		Healthcare workers
		Science,	did not limit our inclusion		(2), Turkey (1), United	Studies with		(nurses 45%, doctors
		Google	to peer-reviewed articles		States (2), Argentina,	minimal		27%, other medical
		Scholar,	only, and included		Brazil, Chile and Mexico	information		workers 11%,
	01-12-	CINAHL,	research letters, briefs		(1), Togo (1), Jordan (1),	on sampling		administration and
	2019 -	SinoMed,	and academic preprints		Iran (3), Pakistan (1),	technique		support staff 1%),
	01-08-	WanfangMed,	stored on servers such as		Taiwan (1), Saudi Arabia	were deemed		unidentified
Li et al., 2021	2020	CNKI, CQVIP	bioRxiv and medRxiv.	65	(1), Switzerland (1).	non-random.	97,333 (70%)	occupation 17%)

(psychological imp mental impact); 2) animal studies, experimental studie Embase, genetic studies; 3) PubMed, not use a validated 01-11- Google instrument to mea 2019 - Scholar, WHO the psychological i 25-05- COVID-19 4) were not in Engli) were lies or did d asure impact;	China (40), Singapore (2), India (2), Japan (1), Pakistan (1), Vietnam (1), Iran (4), Israel (1), Italy (4), Spain (2), Turkey (2), Denmark (1), Greece (1), Argentina, Brazil, Chile		Healthcare workers (19), general population (36), Patients (7, cancer (1), psychiatric (1), epilepsy (1), COVID- 19 (2), type 2 diabetes (1)parkinsons disease and care
25-05-COVID-194) were not in EnglLuo et al., 20202020databaselanguage.		Argentina, Brazil, Chile 62 and Mexico (1)	162,639	disease and care givers (1)

		Inclusion:					
		1. Studies which					
		examined the impact of					
		SARS-CoV-2					
		on healthcare					
		professionals.					
		2. Studies which					
		investigated at least one					
		International					
		Classification of Diseases-					
		10th Revision (ICD-10)					
		defined					
		psychiatric condition.					
		3. Use of at least one					
		validated quantitative					
		scoring scale to					
		measure mental health					
		outcomes, or a self-					
		designed one					
		based on a pre-existing,					
		validated scale					
		4. Available in English					
		Language					
		5. Hospital based					
		6. Conducted from 31st					
		December 2019 (when					
		China reported					
		the first case of SARS-					
		CoV-2 in Wuhan) to 17th					
		June 2020					
		Exclusion:		China (27), Thailand (1),			
		1. Studies investigating		Oman (1), Italy (2), India			
		non-hospital–based		and Singapore (1), United			
		HCWs		Kingdom (1), Romania (1),			
		exclusively		Turkey (1), Spain (1), Iran			
31-12-		2. Written in non-English		(2), Jordan (1), Pakistan			
2019 -	MEDLINE,	language		(1), United States (1),			Healthcare workers
17-06-	Embase,	3. Studies with fewer		Singapore (1), Hong Kong	Cross-		(nurses (38), doctors
2020	Medrix	than 20 participants	44	(1), India (1)	sectional (44)	69499 (NR)	(42))

			Inclusion: studies of any population affected by COVID-19 outbreak since December 2019 when China first reported to the WHO. Studies in any language. Studies must report proportions of participants meeting diagnostic criteria using diagnostic interview of symptoms (based on a					
			prior to and after a delineated event related					
			to COVID-19 (e.g. the					
			announcement of the					
			outbreak generally or the					
			location where the		Brazil (1), Canada (1),			
			research took place, prior		Czech Republic (1),			
			to isolation protocols and		Denmark (2), New			
			after initiation, or during		Zealand (1), Germany (1),			General population
			isolation and following		Argentina (2), India (2),			(23), University
		MEDLINE	relaxation of		Italy (1), Spain (2), The			studnets (9), those
		(Ovid) <i>,</i>	restrictions). Mental		Netherlands (2), China			with pre-existing
		PsychINFO	health symptoms are		(18), Japan (2), United			chronic medical
		(Ovid),	defined broadly and will		States (5), United			conditions (7),
		CINAHL,	include, for example,		Kingdom (8), Switzerland			medical staff (4),
		EBMASE	symptoms or indicators		(1), Australia (1), United			children and
		(Ovid), Web of	of anxiety, depression,		States, United Kingdom,			adolescents (3),
		Science, China	stress, loneliness, anger,		Canada, Ireland (1),			young adults (2),
		National	grief, or other emotional		Canada, France, United	Longitudinal		sexual and gender
		Knowledge	disturbance.		Kngdom, United States	(22), pre and		minority people (1),
	31-12-	Infrastructure,			(1),Canada, United States,	post		pre-existing mental
	2019	Wanfang	Exclusion: studies with		United Kngdom, Belgium,	measurement	426 724 (ND)	health conditions
Thomb et al., 2020	onwards	database	<100 participants.	54	Italy (1)	(32)	136,724 (NR)	(1).

			Inclusion: 1) authors reported risk estimates (odds ratio [OR] and 95% confidence interval [CI]) of factors associated with higher odds of self- reported psychological distress (e.g. anxiety, depression, distress, stress, post-traumatic stress, and insomnia) using standardized and validated psychometric tools; 2) studies reported at least one of the pre- defined factors: gender, age, rural residence, and SES strata (education, income, and employment status); and 3) articles were original, peer-reviewed cross- sectional studies and published in English or					
Wang et al., 2020	12-2019 - 15-07- 2020	Pubmed, EMBASE, Scopus, Cochrane Library, PsycINFO, WHO COVID database	Chinese languages. Exclusion: 1) were not relevant (not using pre- defined factors as the exposure or psychological distress of COVID-19 as the outcome); 2) did not report the OR of factors (e.g. studies using linear regression analyses) or associated 95% CI; 3) were animal or experimental studies, reviews, or meta-	68	China (39, Japan (1), Vietnam (1), Italy (6), United Kingdom (2), Spain (2), Turkey (2), Slovenia (1), Albania (1), France (1), Ireland (1), United States (3), Colombia (1), Iran (1), Israel (1), Saudi Arabia (1), Jordan (1), India (2), Tunisia (1)	NR	28,830 (NR)	General population, Pregnant women (3), high school students and college students (2), patients (10), health care workers (2), children and adolescents (5)

	analyses; 4) were conducted exclusively among healthcare professionals. Eligibility was assessed by first screening titles and abstracts, followed by full-text reviews.			

	01-01- 2019 -	PubMed, EMBASE, and Web of	Inclusion: Studies were included if they reported the prevalence rates of depression, anxiety, insomnia, post-traumatic stress disorder (PTSD), and/or other mental health disorders among pregnant and/or postpartum women during the COVID-19 pandemic. Studies were also included if they reported data from which prevalence rates could be calculated. Exclusion: Letters, case		China (7), United States (3), Turkey (3), Italy (3), Canada (2), Japan (1),	Cross- sectional		
Yan et al., 2020	19-09- 2020	Science databases	reports, or reviews were excluded.	23	Belgium (1), Colombia (1), Sri Lanka (1), Israel (1).	(19), Case- control (4)	20,596 (100)	Pregnant or postpartum women
Tall et al., 2020	2020	uatabases	excluded.	25		CONCION (4)	20,330 (100)	postpartan women

			Inclusion: Studies sampled the same cohort of participants prior to 11/03/20 (date the WHO declared a pandemic) and at least once after this date. Chinese studies were eligible (but analysed separately) if mental health was assessed prior to and after 23/01/20 because substantial social restriction measures were enforced across China from this point. There were no limits on populations sampled. Studies were required to have collected data using a validated multi-item measure of mental		Germany (4), United		
			mental well-being, such as depression (e.g.		States (16), Italy (6), China (4), United States,		
			Patient Health		Canada, Belgium,		
			Questionnaire: PHQ9),		Denmark, Italy, United		
			anxiety (Depression,		Kingdom (1), Turkey (2),		
			Anxiety, Stress Scale:		Switzerland (2), Spain (1),		
			DASS), non-specific		Denmark (1), Norway (1),		
			general mental health		Slovakia (1), Netherlands		
			related functioning and		(4), Sweden (1), United		
			distress (General Health		States, United Kingdom,		
			Questionnaire: GHQ12,		Canada Ireland (1), Japan		
			Kessler) and well-being		(2), Australia (2), India		General population
			(Warwick-Edinburgh		(2), Finland (1), Czech		(75), University
		Duburnel	Mental Wellbeing Scale).		Republic (1), New		students (40), Pre-
	12 2020	Pubmed,	Studies that examined		Zealand (1), Brazil (1), US,		existing MH
	12-2020	SCOPUS, Web	continuous changes (i.e.		Canada, United Kingdom,		conditions (25), pre-
Debineren et el 2021	- 11-01-	of Science,	standardised mean	65	France (1), Netherlands		existing physical
Robinson et al., 2021	2021	PsycINFO	change; SMC) in mental	65	(4), Sweden (1)	~55,015	health (14)

hoalth sumstance ware	ĺ
health symptoms were	
eligible, as was change in	
the % of the sample	
meeting questionnaire	
specific cut-offs for	
clinically relevant/likely	
serious mental health	
problems were eligible	
(i.e. Odds Ratio). Studies	
were required to sample	
the same participants	
using the same measure	
of mental health pre and	
post-pandemic (repeated	
cross-sectional studies	
were not eligible). If only	
a sub-sample of	
participants were	
followed up across	
survey waves, only data	
from the sub-sample	
were eligible. If multiple	
articles reported on data	
from the same cohort of	
participants, the article	
with the largest number	
of post-pandemic follow-	
up data collection points	
was included. Journal	
articles and pre-prints	
were eligible	
Exclusion: Interventions	
to improve mental health	
during the pandemic	
were not eligible. As our	
focus was on mental	
health symptoms,	
ineligible measures	
included loneliness,	

stress and physical health related quality of life.		

			Inclusion: a. Context: COVID-19 epidemic in China b. Population: frontline HCWs, general HCWs, and general adult population c. Outcome: at least one mental disorder outcomes, e.g., anxiety, depression, distress,					
			general psychological symptoms (GPS), insomnia, and PTSD d. Instrument: validated scales with cutoff points for the mental health outcomes e. Language: English.					
			Exclusion: a. Population: children, adolescents, or specific niche adult populations such as COVID-19 patients, inpatients or other patients, adults under quarantine, pregnant/postpartum women b. Methodological					
Chen et al., 2021	10-11- 2019 - 16-11- 2020	Pubmed, EMBASE, Web of Science	approaches: non-primary studies such as reviews or meta-analyses, qualitative or case studies without a validated instrument, interventional studies, interviews, or news reports	131	China (131)	Cross- sectional (126), Cohort (5)	630,244	Frontline Healthcare workers (47), General Healthcare workers (46), General population (78)




Table A7: Summary of results of included systematic reviews

Church ID	A	Desculto non onte d	Demmanai em esele	De sulte non onte d	DTCD	Desculto non onte d	Other seeles	Desculto non onte d
Study ID	Anxiety scales (N)	Results reported	Depression scale	Results reported	PTSD	Results reported	Other scales	Results reported
		The pooled		The pooled				
		prevalence of		prevalence is				
		anxiety among		15.97% CI 95%				
		participants is		[13.24%;19.13%].				
		15.15% CI 95%		Heterogeneity in				
		[12.29%;18.54%].		the results (I2 =				
		There is		99.44) (Higgins et				
		heterogeneity in	Beck depression	al., 2003).				
		the results (I2 =	inventory (2),					
	Beck Anxiety	99.58).	Self-rating	No differences in				
	Assessment (1),		Depression Scale	the prevalence of				
	General Anxiety	No differences in	(4), Depression	depression		The pooled		
	Disorder 7 item	the prevalence of	Anxiety Stress	between citizens		prevalence of		
	(24), General	anxiety between	Scale 21 item (7),	(k=28, 17.05, 95%		PTSD among		
	Anxiety Disorder	citizens (k=31,	Beck Depression	CI [13.03;22.01])		participants is		
	2 item (3), Self-	14.62, 95% CI	Inventory-II (1),	and HCW		21.94% CI 95%		
	rating Anxiety	[10.69;19.69])	WHO-Five Well	(k=18,13.75, 95%		[9.37%;43.31%].		
	Scale (5),	and HCW (k=23,	being Index (1),	CI [11.04;16.96]),		There is		
	Depression	15.86, 95% CI	Patient Health	(z = -1.24, p >		heterogeneity in		
	Anxiety and	[12.22;20.33]), (z	Questionnaire 9	0.05).		the results $(12 = 0.05)$ (Ultrains at		
	Stress Scale 21	= 0.40, p > 0.05).	item (14),	N 1100 1	PTSD Checklist-	99.85) (Higgins et		
	item (7),	N. 1966	Hamilton	No difference in	Civilian version	al., 2003).		
	Hamilton Anxiety	No difference in	Depression Scale	the prevalence of	(2), PTSD	No. differences in		
	Scale, Hospital	the prevalence of	(2), Hospital	depression in	Checklist for	No difference in		
	Anxiety and	anxiety in studies	Anxiety and	studies	DSM-5 post	the prevalence of		
	Depression (1),	conducted in	Depression Scale	conducted in	traumatic	PTSD between		
	Screen for Child	China (k=33,	(1), Patient	China (k=34,	symptoms	citizens (k=9,		
	Anxiety Related	13.49, 95% CI	Health	16.23, 95% Cl	subscale (2),	22.43, 95% Cl		
	Emptional	[9.90;18.11])	Querstionnaire 4	[13.02;20.04])	Impact of Events	[7.62;50.32]) and		
	Disorders (1),	compared to	item (1), Patient	compared to	Scale-Revised (8),	HCW (k=4, 20.91,		
	Patient Health	studies	Health	studies	Global	95% CI		
Count at al. 2022	Questionnaire 4	conducted in	Questionnaire 2	conducted in	Psychotrauma	[5.01;57.00]), (z =		
Cenat et al., 2020	item (2),	other countries	item (2).	other countries	Screen (1).	09, p > 0.05).		

		(k=18, 19.02, 95%) CI [15.01;23.80]), (z = 1.78, p > 0.05). However, we might lack statistical power to detect a difference between the two groups. No differences in the prevalence of anxiety between males (k=6, 14.19, 95% CI [7.14;26.23]) and females (k=6, 17.87, 95% CI [9.64;30.73]), (z = -0.51, p > 0.05).		(k=12, 16.92, 95% CI [11.78;23.70]), (z = .20, p > 0.05). No differences in the prevalence of depression between males (k=9,19.05, 95% CI [11.17;30.57]) and females (k=9, 22.93, 95% CI [15.16;33.14]), (z = -0.57, p > 0.05).		
		Global prevalence of anxiety of 21.3% (95%Cl:19.0- 23.6%). Asia had lower levels of anxiety (17.9%, 95%Cl:15.4-20.3) compared to other regions of		Global prevalence of 24.0% (95% Confidence Interval (Cl): 21.0- 27.1%) of depression; Depression was observed among 17.6% (95%Cl:15.4- 19.8%) in Asia,		
Castaldelli-Maia et al., 2020	Generalized Anxiety Disorder 7 item (cut-off 10+)	the world (28.6%, 95%CI:22.6-34.6). Europe did not differ from Asia and the other regions of the world.	Patient Health Questionnaire 9 item (cut off 10+)	among 26.0% (95%CI: 22.9- 29.05) in Europe, and among 39.1% (95%CI: 29.2- 49.1%) in other regions of the		

1 1	1		1	1 1
	China had a lawar	world.		
	China had a lower	Ching had a lawar		
	prevalence of	China had a lower		
	anxiety (15.5%,	prevalence of		
	95%CI:13.1-	depression		
	17.9%) compared	(16.2%,		
	to all other	95%CI:13.7-		
	countries (25.6%,	18.2%). than in		
	95%CI:23.1-28.0).	other countries		
	The number of	(29.0%,		
	studies in each of	95%CI:24.8-33.2).		
	the other			
	countries was too	No significant		
	restrictive to	differences by		
	make country-	population type,		
	specific	country income		
	comparisons (i.e.,	level, or being a		
	U.S. was the	local study.		
	second country			
	with more studies	Meta-regression:		
	having just 4	Both in the 2- and		
	studies).	4-week physical		
		distancing		
	No significant	models, previous		
	differences by	depression, older		
	population type,	studies, and other		
	country income	region of the		
	level, or being a	world than		
	local study.	Asia/Europe were		
		associated with		
	Meta-regression:	depression. In		
	Both in the 2- and	addition, patient		
	4-week physical	studies had a		
	distancing	higher prevalence		
	models, the	of depression in		
	closure of public	the 2-week		
	transportation	physical		
	was associated	distancing model.		
	with anxiety.	No significant		
	Student studies	association with		
	had lower levels	physical		
LI		physical		

	of anxiety in both models. No other significant association between physical distancing measures and depression or anxiety were found.	distancing implementation measures was found in both models.		
Cavicchioli et al., 2021				

				Overall mean of		
				EPDS scores was		
				9.84 (95% CI 8.36-		
				11.33; p<.001; l2		
				= 98.7%). As		
				compared to the		
				pre-pandemic		
				period, the		
				pooled findings		
				showed that the		
				EPDS score (SMD		
				= 0.40, 95% CI: -		
				0.05-0.86,		
				p=0.083; I2 =		
		Anxiety score was		98.0%) was		
		significantly		higher among		
		higher during the		study subjects		
		pandemic when		during COVID-19		
		compared with		pandemic;		
		pre-pandemic		however, this		
		time (SMD = 0.82,	Edinburgh	difference was		
		95% CI: 0.49-1.16,	Postnatal	not statistically		
Hessami et al.,	Stae-Trait Anxiety	p<.001; I2 =	Depression	significant		
2020	Inventory	90.2%).	Survey	(p=0.083).		

	The pooled prevalence of moderate anxiety was 22.1% (95% Cl, 18.2%-26.3%) across 57 studies, when defining anxiety as a score at or above the cut-off for moderate symptomology, or the cut-off noted		Estimated pooled prevalence of moderate depression 21.7% (95% Cl, 18.3%- 25.2%) across 55 studies, when defining depression as a score at or above the cut-off for moderate symptomology, or			
	by the author to be clinically relevant. Individual study estimates ranged from 5.2% to 89.7%, and there was significant evidence of	Patient Health Questionnaire 9	the cut-off deemed by the author to be clinically relevant. Individual study estimates ranged from 5.3% to 57.6%. Evidence of high		Pooled prevalence estimate of moderate PTSD was 21.5% (95%	
Generalized Anxiety Disorder 7 item (29), Self- Rating Anxiety Scale (9), Depression Anxiety Stress	between-study heterogeneity (I2 = 99.4%, p<0.001). The prevalence of	item (28), Self- rating Depression Scale (7), Depression Anxiety Stress Scale 21 item (6), Patient Health	between-study heterogeneity (I2 = 99.3%, p<0.001). The pooled		Cl, 10.5%-34.9%) when defined as a score at or above the cut-off for moderate symptomology, or the cut-off noted	
Scale 21 item (6), Hospital Anxiety and Depression Scale (3), Generalized Anxiety Disorder	mild anxiety was estimated at 38.3% (95% Cl, 32.6%-44.3%) when defining the presence of	Questionnaire 2 item (3), Hospital Anxiety and Depression Scale (HADS), Patient Health	estimate of mild depression was 36.1% (95% Cl, 31.3%-41.0%) when defining the presence of	Impact of Events Scale -Revised (5), Post-Traumatic Stress Dsorder Self-Rating Scale (1), Global	by the author to be clinically relevant. Individual study estimates ranged from 2.9% to	
2 item (3), Patient Health Questionnaire 4 item (2), Hamilton Anxiety Rating Scale (2)	anxiety symptoms as the cut-off for mild anxiety, or the cut-off for a clinically relevant score	Questionnaire 4 item (2), Center for Epidemiologic Studies Depression Scale (2)	depressive symptoms as a score at or above the cut-off for mild symptomology, or	Psychotrauma Scale-PTSD (1), PTSD Checklist (1), PTSD Checklist - Civilian version (1)	49.5%, and there was evidence of between-study heterogeneity (I2 = 99.7%, p<0.001).	

1	1	
		that noted by the
		author to be
	Prevalence	clinically relevant.
	estimates of	
	moderate anxiety	
	differed	Prevalence
	significantly	estimates of
	across region	moderate
	(p<0.001). The	depression were
	studies from the	compared
	Middle-East	between region:
	yielded the	East Asia, South
	highest pooled	Asia, the Middle-
	prevalence	East, Europe,
	estimate (28.9%;	North America,
	95% Cl, 21.6%-	West Africa and
	36.8%), and the	South America
	lowest was	(Table 1). The
	calculated across	estimates of
	the studies of	these regions
	North America	significantly
	(14.8%; 95% CI,	differed (p =
	13.9%-15.7%).	0.001). Pooled
	The 37 studies	estimates were
	from China	highest for
	yielded a pooled	studies
	prevalence	conducted in the
	(19.1%; 95% CI <i>,</i>	Middle-East
	15.5%-23.0%)	(34.6%; 95% CI,
	slightly lower	25.1%-44.9%),
	than calculated	although
	across all studies	relatively wide
	from East Asia	confidence
	(20.5%; 95% CI,	intervals were
	15.7%-25.8),	present. Pooled
	although the	estimates were
	confidence	lowest in North
	intervals overlap,	America (18.7%;
	suggesting similar	95% Cl, 17.8%-
	distribution of	19.7%) and East
	estimates.	Asia (19.1%; 95%

1	1		
		Cl, 15.2%-23.4%).	
		Pooling the	
	29 studies used	estimates of the	
	the GAD-7, and	37 studies from	
	the pooled	China only did not	
	prevalence	result in a	
	estimate across	substantially	
	these studies was	different estimate	
	20.8% (95% CI,	to that of all	
	17.2%-24.7%).	studies from East	
	The highest	Asia.	
	pooled		
	prevalence was		
	calculated from	28 of the included	
	the studies using	studies used the	
	HADS (32.0%;	PHQ-9 to screen	
	95% Cl, 10.8%-	for depressive	
	58.1%), although	symptoms, and	
	this group	when estimates	
	included only	were pooled,	
	three studies and	these studies	
	the confidence	yielded a	
	intervals are	prevalence of	
	wide. Those	21.9% (95% Cl,	
	studies using the	16.2%-28.2%).	
	SAS yielded the	The highest	
	lowest pooled	pooled	
	estimate (10.1%;	prevalence	
	95% Cl, 5.6%-	estimate was	
	15.6%), although	calculated across	
	it should be noted	the three studies	
	that the	using the HADS	
	confidence	(29.2%; 95% CI,	
	intervals overlap	16.3%-60.2%),	
	with those of the	with the lowest	
	HADS. The pooled	estimate from the	
	estimates of	six studies using	
	these subgroups	the DASS-21	
	differed	(18.7%; 95% CI	
	significantly	9.6%-30.0%),	
	(p<0.001).	although it is	
	(P. 0.00-).		

1		worth noting the	
		wide and	
	Data on the		
		overlapping confidence	
	proportion of		
	participants in	intervals,	
	contact with	suggesting	
	patients infected	imprecise	
	with COVID-19	estimates. The	
	was provided in	subgroup analysis	
	27 studies only.	suggested	
	Studies in which	evidence of	
	more than 50% of	differential	
	participants were	prevalence	
	in contact with	estimates	
	patients with	between	
	COVID-19	screening tools	
	demonstrated a	(p<0.001).	
	higher prevalence		
	of anxiety (25.7%;		
	95% CI, 17.4%-	There was no	
	34.9%), compared	evidence of	
	to studies in	differential	
	which 50% or	prevalence	
	fewer	estimates across	
	participants were	other subgroups:	
	in contact (17.4%;	sample	
	14.5%-20.4%),	size (p = 0.81);	
	although	publication status	
	evidence of this	(p = 0.30); the	
	difference was of	proportion of	
	borderline	female	
	significance (p =	participants (p =	
	0.06).	0.91); and	
		the proportion of	
		participants in	
	Prevalence	contact with	
	estimates did not	infected patients	
	significantly differ	(p = 0.92).	
	based on sample	Moreover, none	
	size (p = 0.73);	of the	
	publication status	covariates	
L I	particular		

i			1 1	1
	(p = 0.13); and	included in the		
	the proportion of	meta-regression		
	female	model explained		
	participants (p =	the presence of		
	0.25). Based on	heterogeneity.		
	the univariate			
	meta-regression			
	analyses, there			
	was evidence that			
	the following			
	variables			
	explained			
	between study			
	heterogeneity:			
	sampling method			
	(p = 0.03);			
	screening tool (p			
	= 0.05);			
	publication status			
	(p = 0.03); and			
	the proportion of			
	participants in			
	contact with			
	infected patients			
	(p = 0.04). The			
	subsequent multi-			
	variate meta-			
	regression model			
	suggested that			
	these variables			
	explained			
	approximately			
	17% of the			
	between-study			
	variance			
	(adjusted R2 =			
	17.4%).			

		The overall prevalence of anxiety was 33% (28%-38%) with substantial heterogeneity (12=99.7%, P<0.001).		The overall prevalence of depression was 28% (23%-32%) with substantial heterogeneity (12=99.6%, P<0.001).		
		The prevalence of anxiety was higher among patients (56% [39%-73%]) compared to healthcare workers (26% [18%-34%]) and the general public	Different validated scales used to measure depression included the Beck Depression Inventory, the Center for Epidemiologic Studies Depression Scale,	The prevalence of depression was higher among patients (55% [48%-62%]) compared to healthcare workers (25% [17%-33%]) and the general public		
	Beck Anxiety Inventory, the Depression, Anviety and	(32% [25%-39%]), and the prevalence was similar between healthcare workers and the	the Children's Depression Inventory— Short Version, the Depression, Anxiety and	(27% [22%-33%]), and the prevalence was similar between healthcare workers and the	The prevalence of post-traumatic stress symptoms/disord ers was the bighest among	
	Anxiety and Stress Scale-21, the Generalized Anxiety Disorder- 2/-7, the Hamilton Anxiety Rating Scale, the	general public with overlapping 95% confidence intervals. Among	Stress Scale-21, the Edinburgh Postnatal Depression Scale, the Hamilton Depression Rating Scale, the	general public with overlapping 95% confidence intervals. Among	highest among patients with COVID-19 (93% [92%-95%]), which was higher than that reported in	
	Hospital Anxiety and Depression Scale, the Patient Health Questionnaire-4/- 9, and the Zung Self-Rating	healthcare workers, the prevalence ranged between 7% (5%-9%) in Singapore to 57% (52%-63%) in	Hospital Anxiety and Depression Scale, the Patient Health Questionnaire-4/- 9, and the Zung Self-Rating	healthcare workers, the prevalence ranged between 9% (7%-12%) in Singapore to 51% (48%-53%) in	healthcare workers and the general public (prevalence ranged between 3% [2%-4%] to 16% [15%-	
Luo et al., 2020	Anxiety Scale	Italy.	Depression Scale.	China.	17%]).	

1	1 1	1		1
	Among the	Among the		
	general public,	general public,		
	the highest	the highest		
	prevalence of	prevalence of		
	anxiety was	depression was		
	observed in Italy	observed in Italy		
	(81% [80%-83%]),	(67% [65%-69%]),		
	and the	and the		
	prevalence	prevalence		
	ranged between	ranged between		
	8% (7%-10%) and	10% (9%-11%)		
	55% (45%-64%).	and 60% (50%-		
		70%).		
	Among patients			
	with pre-existing	Among patients		
	conditions and	with cancer and		
	COVID-19, the	COVID-19, the		
	prevalence of	prevalence of		
	anxiety was	depression		
	consistently high;	ranged between		
	it ranged	50% (41%-59%)		
	between 40%	among cancer		
	(30%-50%) among	patients and 65%		
	patients with type	(51%-77%) among		
	2 diabetes in	patients with		
	India and 82%	COVID-19 in		
	(74%-88%) among	China. Psychiatric		
	patients with	patients reported		
	Parkinson's	a prevalence of		
	disease in Iran.	moderate-to-		
		severe depression		
		of 22% (13%-		
	The anxiety	32%).		
	prevalence was	52701.		
	47% (34%-61%)			
	among patients			
	infected by			
	COVID-19, and it			

was 50% (41 59%) among cancer patie and 58% (47 68%) among caregivers o patients wit Parkinson's disease. In addition, psychiatric patients rep a prevalence moderate-to severe anxie 24% (14%-3	g ents 7%- g of th borted e of o- ety of				
---	---	--	--	--	--

		Using the cut-off score ≥10, seven		PHQ-9: Using the cut-off score ≥10, eight studies		Using the cut-off score >24/25 four	
		studies showed		showed		studies showed	
	Generalized	anxiety prevalence	Patient Health	depression prevalence		PTSD prevalence ranging from	
Sanghera et al.,	Anxiety Disorders	ranging from	Questionnaire 9	ranging from	Impact of events	7.4% to	
2020	7 item (11)	12.3% to 35.6%.	item (10)	13.5% to 44.7%.	scale -revised (7)	37.4%	

	l	Pre/post		Pre/post onset of			Pre/post
		pandemic onset		COVID-19			pandemic onset
		One study		outbreak			Three studies
		, reported that		One study			compared
		compared to		reported that			responses from a
		participant		compared to			representative
		responses		participant			sample of British
		completed at age		responses			adults (UK
		26, the COVID-19		completed at age			Household
		data		26, the COVID-19			Longitudinal
		demonstrated a		data			Study, UKHLS)
		small increase in		demonstrated			between wave 9
		continuous		negligible			and the COVID-19
		anxiety scores		changes in			wave. All of them
		(N= 1811, 0.26		continuous			reported that
		standard		depression scores			there was a small
		deviations, 95% CI	Pre/post	(N= 2219, -0.11			increase in
		0.21 to 0.30).	pandmic onset:	standard			general mental
			Short Mood and	deviations, 95%			health symptoms
		A longitudinal	Feelings	CI -0.06 to -0.15)			over time.
		cohort study of	Questionnaire (1),				
		sexual and gender	Patient Health	A longitudinal			
	Pre/post	minority people,	Questionnaire (1),	cohort study of			One study
	pandemic onset:	reported a large	General Health	sexual and gender			reported that
	Generalized	increase in	Questionnaire (1).	minority people,			SCL-90 total
	Anxiety Diorder-7	anxiety (0.54	Changes during	reported a small			scores during
	(4), Gneralized	standard	pandemic:	increase in		Pre/post	COVID-19 were
	Anxiety Disorder-	deviations, 95% CI	Patient Health	depression		pandemic:	lower than the
	2 (1). Changes	0.48 to 0.60)	Questionnaire	(N=2288, 0.19		General Health	corresponding
	during the	following the	(1),Beck	standard		Questionnaire-12	pre-COVID scores
	pandemic:	COVID-19	Depression	deviations, 95%		(1), Symptom	(N= 2603, -0.20
	Generalized	outbreak.	Inventory (1),	CI 0.14 to 0.25)		Checklist-90-	standard
	Anxiety Disorder-		Composite	following the		Revised (2),	deviations, 95% CI
	7 (1), State Trait	One study	International	COVID-19		Mental Health	-0.25 to -0.14).
	Anxiety	reported that	Diagnostic	outbreak		Inventory-5 (2).	
	Inventory,	there was a small	Interview (1),			Changes during	
	Psychological	increase in	Psychological	One study		pandmic: Kessler	One study
	Questionnaire on	anxiety scores	Questionnaire on	reported that		Psychological	reported that
	Emergency	after lockdown	an Emergent	there was a small		Distress Scale,	there was a
Thomb et al.,	Events in Public	(N=3563, 0.16	Event in Pub,ic	increase in		Brief Job Stress	significant
2020	Health (1)	standard	Health (1)	depression		Questionnaire	increase (7.99%)

1 1 1	deviations, 95% CI	among both non	in the propertion
	0.12 to 0.21).	caregivers	in the proportion of participants
	0.12 (0 0.21).		
		(N=6178, 0.25	who scored
	One study	standard	above a mental
	reported a small	deviations, 95%	health function
	increase in	CI 0.22 to 0.29)	threshold (SCL-90
	anxiety scores	and caregivers	≥ 160) during the
	(N= 1811, 0.14	(N=1349, 0.28	epidemic period
	standard	standard	compared with
	deviations, 95% Cl	deviations, 95%	that of freshmen
	0.09 to 0.19).	CI 0.20 to 0.35)	when they were
		after the COVID	enrolled.
	One study	outbreak	
	reported that the		
	proportion of	One study	One study
	anxiety symptoms	reported a small	reported that
	in the elderly	increase in	negligible
	population	depression scores	changes in mental
	increased 5.15%	(N= 1811, 0.16	health (N=3983, -
	over time.	standard	0.01 standard
		deviations, 95%	deviations, 95% CI
	Changes during	CI 0.11 to 0.21)	-0.05 to 0.04)
	the pandemic		following the
	One study	Changes during	COVID-19
	compared	the pandemic	outbreak.
	responses of	One study	
	36,520 adults in	compared	
	the UCL COVID -	responses of	Study 45398
	19 Social Study, a	36,520 adults in	reported that
	panel study	the UCL COVID -	loneliness of
	weighted to	19 Social Study, a	older people
	population	panel study	increased (N=
	proportions. Data	weighted to	1679, 0.52
	were collected for	population	standard
	20 weeks during	proportions. Data	deviations, 95% CI
	the course of the	were collected for	0.45 to 0.59)
	pandemic and	20 weeks during	while mental
	latent growth	the course of the	health remained
	models were	pandemic and	roughly stable
	fitted, estimating	latent growth	(0.12 standard
	an average 0.10	models were	deviations, 95% CI
	an average 0.10	ווטעכוז שכוכ	

I			
	weekly point	fitted, estimating	0.05 to 0.19) over
	decrease in	an average of	time
	anxiety symptoms	0.11 weekly point	
	over the 20	decrease in	
	weeks.	depression	Changes during
		symptoms over	the pandemic
	One study	the 20 weeks	An internet-based
	reported that		survey of
	levels of anxiety	One study	Japanese people
	tended to	reported that	conducting in two
	decrease (N=	depression	phases: early
	6057, -0.10	tended to	phase and
	standard	increase slightly	community-
	deviations, 95% Cl	(N= 6057, 0.09	transmission
	-0.13 to -0.06)	standard	phase,
	among the	deviations, 95%	demonstrated a
	general	CI 0.05 to 0.12)	significant
	population	among the	increase of
		general	psychological
	One study	population	distress between
	reported anxiety		the two phases
	levels remained	One study	(N= 2078, 0.15
	stable (N= 1390, -	targeted school-	standard
	0.02 standard	age children (ages	deviations, 95% CI
	deviations, 95% CI	from 6 through	0.09 to 0.21).
	-0.10 to 0.05),	17 years) in	
		China, reported	One study
		that the mean	reported that
		CDI-S score	mental health
		significantly	symptoms
		decreased	increased slightly
		between the two	among health
		surveys: 4.19	care workers
		before school	(N=111, 0.23
		closure and 3.90	standard
		during school	deviations, 95% CI
		closure (N= 2427,	0.03 to 0.50)
		-0.11 standard	while remained
		deviations, 95%	roughly stable
		Cl -0.16 to -0.05).	among non
			health care
			licuiti tare

		One study reported that depression level increased negligibly (N= 1390, 0.08 standard deviations, 95% CI 0.00 to 0.15),		workers (N= 904, -0.02 standard deviations, 95% CI -0.12 to 0.07) during two months of the COVID-19 outbreak.

	Depression Anxiety and Stress Scale-21 (2), Generalised Anxiety Disorder- 7 (20), Hamilton Anxiety Rating Scale (1), Hospital Anxiety and Depression Scale (3), Gereneralised Anxiety Disorder- 2 (3), Zung self- rating anxiety scale (4), Screen for Child Anxiety Related Disorders (3), Beck Anxiety	The overall prevalence of anxiety was 33% (95% CI: 28%- 39%; I2 = 99.9%). The meta- regression analysis suggested no statistical	Depression Anxiety Stress Scale-21 (2), Patient Health Questionnaire-9 (15), Hamilton Depression Scale (1), Center for Epidemiological Studies Depression Scale (1), Hospital Anxiety and Depression Scale (2), Patient Health Questionnaire-2 (3), WHO-5 (2), Childs Depression Inventory (2), Zung self-rating Depression Scale (3), Depression Self-rating Scale for Children (1), Center for Epidemiological Studies (3), Beck Depression Inventory (1), Edinburgh Postnatal Depression Scale	the prevalence of depression was 30% (95% CI: 26%-36%; I2 = 99.8%). The meta-regression analysis suggested no statistical		
	Anxiety Disorder- 2 (3), Zung self-	(95% CI: 28%- 39%; I2 = 99.9%).	Epidemiological Studies (3), Beck	30% (95% CI: 26%-36%; I2 =		
	scale (4), Screen	regression	Inventory (1),	meta-regression		
			-	-		
	(3), Beck Anxiety	statistical	Depression Scale	statistical		
	Inventory (1), State Trait	differences across subgroups of	(1), Impact of Events Scale—	differences across subgroups of		
	Anxiety Inventory	studies using	Revised (1),	studies using		
	(3), Patient	different	Patient Health	different		
	Health	instruments or	Questionnaire-8	instruments or		
	Questionnaire-4	cut-off points (see	(1), Patient	cut-off points (see		
Wang et al., 2020	(1)	separate tab).	Health	separate tab)		

	Questionnaire-2 (1).			

	Beck Anxiety Inventory (1),	Anxiety severity mild 24% (95% Cl = 11%-40%, I2 = 99.0%) moderate 17% (95% Cl = 4%- 36%, I2 = 99.6%) severe 7% (3%- 13%, I2 = 97.9%) Pooled prevalence of		The pooled prevalence of depression among pregnant women was 31% (95% CI 20–42%, I2 = 99.4%). Removing those studies with a		
	Anxiety and Depression Checklist -K10 (1), Generalised Anxiety Disorder- 7 (4), Social Anxiety Questionnaire (2), Patient Reported	anxiety among pregnant women was 37% (95% Cl 25–49%, 12 = 99.4%). Following removing studies with high risk of bias pooled prevalence of	Edinburgh depression scale (1), Edinburgh	high risk of bias pooled prevalence of depression among pregnant women of 27% (95% Cl 17–40%, l2 = 99.5%). Sensitivity		
	Outcomes Measurement Information System-Anxiety (1), Zung Self- Rating Anxiety Scale (1), State- Trait Anxiety	anxiety among pregnant women of 34% (95% CI 22–47%, I2 = 99.4%). Sensitivity analysis, prevalence of anxiety among	Postnatal Depression Survey (9), Patient Health Questionnaire,-2 (1), Patient Health Questionnaire-9	analysis, removing those that affected the pooled prevalence by more than 2%: prevalence of depression		
Yan et al., 2020	Inventory (2), Hospital Anxiety and Depression Scale (1).	pregnant women was 39% (95% Cl 25–53%, I2 = 99.1%).	(1), Hospital Anxiety and Depression Scale, (1)	among pregnant women was 29% (95% Cl 23–35%, l2= 97.8%).		

1	I		Revised Children's			I	General Health	Time analyses.
			Anxiety and				Questionnaire (2)	Change in
			Depression Scale				(Disstress/non-	symptoms from
	Revised Child		(3), Depression				specific MH),	pre-pandemic
	Anxiety and		Anxiety and				Unidimentional	levels became
	, Depression Scale		, Stress Scale-21				Positive MH Scale	smaller over each
	(2), Depression		(7), Brief				(1) (Well-being),	month (monthly
	Anxiety and		Symptom				Brief Symptom	change
	Stress Scale (7),		Inventory				Inventory (2)	coefficient =057
	Brief Symptom		Depression (2),				(Psychotic	[95%CI:100 to -
	Inventory (2),		Hospital Anxiety				Symptoms),	.013], z = 2.57, p =
	Hospital Anxiety		and Depression				Eating Disorders	.010). To
	and Depression		Scale (2), Patient				Examination (1)	illustrate, among
	Scale (2), Patient		Reported				(Other MH	post-pandemic
	Reported		Outcomes				Symptoms),	measures of
	Outcome		Measurement				Patient Health	mental health
	Measurement		Information				Questionnaire-4	collected in
	Informaiton		System (1), Child				(2) (Distress/non-	March and April
	System (3), Child		Behaviour				specific MH),	(n = 98) the
	Behaviour		Checklist affective				Short Warwick	change in mental
	Checklist (1),		(1), Patient				Edinburgh MH	health was
	Generalized		Health				Scale (4) (Well-	statistically small
	Anxiety Disorder-		Questionnaire-9				being), Hopkins	and significant;
	7 (13), Beck		(11), Beck				Symptom	SMC = .102 [95%
	Anxiety Inventory		Depression				Checklist (1)	Cl: .026 to .192] z
	(3), Patient		Inventory (3),				(Discress/non-	= 2.22, p = .026).
	Health		Patient Health				specific MH),	Conversely, for
	Questionnaire-4		Questionnaire-8				Community	measures
	(1), Spence Childs		(2), Center for				Assessment of	collected during
	Anxiety Scale (2),		Epidemiological				Psychic	May-July (n = 67)
	State-trait		Studies				experiences (1)	there was no
	Anxiety Scale (1),	There was a small	Depression (2),	There was a small			(Psychotic	significant change
	Sympton	but significant	Strengths and	significant			symptoms),	compared to pre-
	Checklist-90 (1),	increase in	Difficulties	increase in			Kessler 6 (2)	pandemic mental
	Clinical Global	symptoms of	Questionnaire (1),	symptoms of			(Discress/non-	health symptoms;
	Impression Scale	anxiety pre to	Short Mood and	depression pre to			specific MH),	SMC = .067 [95%
	(1), Children's	post pandemic	Feelings	post pandemic			Eating disorders	Cl:022 to .157],
	Yale-Brown	outbreak (SMC =	Questionnaire (3),	outbreak (SMC =			inventory (1)	z = 1.47, p = .141).
	Obsessive	.125 [95% CI: .019	Edinburgh	.216 [95% CI: .135			(Other MH), Child	There was no
Robinson et al.,	Compulsive Scale	to .230], z = 2.31,	Postnatal	to .296], z = 5.24,			Behaviour	robust interaction
2021	(1)	p = .021).	Depression Scale	p < .001)			Checklist (1)	between

(1), Quick	(distress/non- symptom types
Inventory of	specific MH), and time.
Depressive	Brief Problem
Symptomatology	Monitor-
(1), Kandal and	Internalizing Overall change in
Davies	Symptoms (1) MH symptoms:
Depression Scale	(distress/non- From the 165
(1), Hamilton	specific MH), comparisons
Depression Scale	PTSD Checklist (1) drawn from
(1), Patient	(other MH), Mini ~55,015
Health	symptom participants,
Questionnaire 4	checklist (1) overall change in
(1), Patient	(psychotic mental health
Health	symptoms), Social symptoms from
Questionnaire-2	Behaviour pre-post
(1), Children's	Questionnaire pandemic
Depression	Internalizing (1) outbreak was
Inventory (1)	(Distress/non-significant (SMC =
	specific MH), .106 [95% CI: .039
	Suicidal Ideation to .172], z = 3.12,
	Scale (1) (Other p = .002, I2 =
	MH), World 97.8) and
	Health indicative of
	Organisation heterogeneous
	quality of life and small
	mental health increase in
	subscale (1) symptoms
	(Distress/non- (SMC=0.2 is
	specific MH), indicative of a
	Mental Health small effect).
	Inventry (1)
	(Distress/non- There was no
	specific MH), significant change
	Child Trauma in measures of
	Symptom Scale general mental
	(1) (other MH). health (SMD = -
	.030 [95%Cl158
	to .098], z =
	0.457, p = .648).
	There was a
	significant

				decrease in symptoms of psychosis (SMC = 211 [95% Cl: - .376 to046], z = 2.51, p = .012).
				Sub group
				analyses. Across
				sub-groups, we
				found no
				evidence that
				change in mental
				health symptoms
				differed based on
				age, gender, or
				study continent.
				Changes in
				symptoms tended
				to be larger
				among
				participants with
				a pre-existing
				physical health
				condition (SMC =
				.249 [95% CI: .067
				to .431], z = 2.68,
				p = .007)
				compared to the
				general
				population (SMC
				= .118 [95% CI:
				.042 to .193], z =
				3.04, p = .002) .
				Notably, change
				in mental health
				symptoms was
				non-significant in
				samples with pre-
				existing mental

1	1	l			l	
						health conditions
						(SMC =017
						[95% CI:211 to
						.178], z = 0.17, =
						.867). No country-
						level data
						(number of
						COVID
						cases/deaths,
						stringency of
						government
						measures or
						level) explained
						heterogeneity
						between samples
						(ps > .05).
						Change in
						numbers
						exceeding
						questionnaire
						cut-offs for
						mental health
						problems.
						Twenty-four
						comparisons
						across 12 studies
						(~21,825
						participants)
						were included.
						There was a
						significant effect
						(single level
						meta-analysis),
						with increased
						odds of exceeding
						a questionnaire
						cut-off for mental
						health problems
						from pre-post
						pandemic

				(Marginal Odds Ratio = 1.31 [95% Cl: 1.10 to 1.55], z = 3.18, p = .001, I2 = 93.2%), where an OR of 1.5 is considered a small sized effect.

	I		I		1		I
		Predicted		Predicted		Predicted	l
		prevalence rates		prevalence rates		prevalence rates	l
		from meta-		from meta-		from meta-	I
		regression (95%		regression (95%		regression (95%	I
		CI)		CI)		CI)	I
		Mild Anxiety:		Mild Depression:		Mild PTSD:	I
		Frontline		Frontline		Frontline	l
		Healthcare		Healthcare		Healthcare	l .
		Workers: 28%		Workers: 29%		Workers: 32%	1
		(23% - 33%).		(24% - 34%),		(25% - 40%),	l
		General		General		General	1
		Healthcare		Healthcare		Healthcare	ł
		Workers: 22%		Workers: 23%		Workers: 26%	l
		(17% - 26%),		(19% - 27%),		(19% - 33%),	ł
		General		General		General	ł
		population: 23%		population: 24%		population: 27%	I
		(19% - 28%).		(20% - 29%),		(20% - 35%),	l
		Overall: 24% (20%		Overall: 25% (21%		Overall: 28% (22%	1
		- 28%).		- 29%)		- 35%)	l
				,			l
		Moderate		Moderate		Moderate PTSD:	l
		anxiety: Frontline		Depression:		Frontline	l
		Healthcare Staff:	Patient Health	Frontline		Healthcare Staff:	l
		19% (15% - 23%),	Questionnaire	Healthcare Staff:		23% (17% - 29%)	l
		General	(81), Self-rating	20% (17% - 24%),		General	l
		Healthcare	Depression Scale	General		Healthcare	l
		Workers 14%	(17), The Center	Healthcare		Workers 17%	l
	Generalized	(11% - 17%),	for Epidemiologic	Workers 15%	Impact of Event	(12% - 23%),	l
	Anxiety Disorder	General	Studies	(12% - 18%),	Scale-R (12), Post	General	I
	(77), Self-rating	population: 15%	Depression Scale	General	traumatic Stress	population: 19%	l
	Anxiety Scale	(12% - 19%).	(9), Depression	population: 16%	Disorder Checklist	(14% - 24%).	I
	(30), Hospital	Overall: 16% (13%	Anxiety Stress	(13% - 20%).	for DSM-5 (8),	Overall: 20% (15%	I
	Anxiety	- 19%).	Scale (7), Hospital	Overall: 16% 17%	Post Traumatic	- 25%)	l
	Depression Scale	± <i>370</i>].	Anxiety	(14% - 20%)	Scress Disorder	23/01	l
	(7), Depression	Severe anxiety:	Depression Scale	(17/0 20/0)	Checklist - Civilian	Severe PTSD:	l
	Anxiety Stress	Frontline	(7), Hamilton	Severe	Version (8),	Frontline	l
	Scale (6),	Healthcare	Depression Scale	Depression:	Impact of Events	Healthcare	I
			(5), Beck	Frontline	Scale-6 (1), The	workers: 6% (3% -	l
	Hamilton Anxiety	workers: 4% (2% -	• • •		• •		l
	Rating Scale (6),	6%). General	Depression	Healthcare	Primary Care	11%) General	l
	Beck Anxiety	Healthcare	Inventory-II (1),	workers: 5% (3% -	PTSD Screen for	Healthcare 3%	l
Chen et al., 2021	Inventory (1)	Workers 2% (1% -	WHO-5 (1)	7%). General	DSM-5 (1)	(1% - 7%),	L

3%). General population 2% (1% - 4%). Overall 3% (2% - 4%).	Healthcare Workers 2% (1% - 4%), General population 3% (1% - 5%). Overall 3% (2% - 5%)	General population4% (1% - 8%). Overall 5% (2% - 8%)	

Review refences

Cenat JM, Blais-Rochette C, Kokou-Kpolou CK, Noorishad PG, Mukunzi JN, McIntee SE, et al. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis. Psychiatry Research. 2021;295:113599.

Castaldelli-Maia JM, Marziali ME, Lu Z, Martins SS. Investigating the effect of national government physical distancing measures on depression and anxiety during the COVID-19 pandemic through meta-analysis and meta-regression. Psychological Medicine. 2021:1-46.

Cavicchioli M, Ferrucci R, Guidetti M, Canevini MP, Pravettoni G, Galli F. What Will Be the Impact of the Covid-19 Quarantine on Psychological Distress? Considerations Based on a Systematic Review of Pandemic Outbreaks. Healthcare. 2021;9(1):19.

Chen X, Chen J, Zhang M, Chen RZ, Dong RK, Dong Z, et al. One Year of Evidence on Mental Health in the COVID-19 Crisis-A Systematic Review and Meta-Analysis. medRxiv. 2021.

Hessami K, Romanelli C, Chiurazzi M, Cozzolino M. COVID-19 pandemic and maternal mental health: a systematic review and meta-analysis. Journal of Maternal-Fetal & Neonatal Medicine. 2020:1-8.

Li Y, Scherer N, Felix L, Kuper H. Prevalence of depression, anxiety and post-traumatic stress disorder in health care workers during the COVID-19 pandemic: A systematic review and meta-analysis. PLoS ONE [Electronic Resource]. 2021;16(3):e0246454.

Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public - A systematic review and meta-analysis. Psychiatry Research. 2020;291:113190.

Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic. medRxiv. 2021.

Sanghera J, Pattani N, Hashmi Y, Varley KF, Cheruvu MS, Bradley A, et al. The impact of SARS-CoV-2 on the mental health of healthcare workers in a hospital setting-A Systematic Review. Journal of Occupational Health. 2020;62(1):e12175.

Thombs BD, Bonardi O, Rice DB, Boruff JT, Azar M, He C, et al. Curating evidence on mental health during COVID-19: A living systematic review. Journal of Psychosomatic Research. 2020;133:110113.

Wang Y, Kala MP, Jafar TH. Factors associated with psychological distress during the coronavirus disease 2019 (COVID-19) pandemic on the predominantly general population: A systematic review and meta-analysis. PLoS ONE [Electronic Resource]. 2020;15(12):e0244630.

Yan H, Ding Y, Guo W. Mental Health of Pregnant and Postpartum Women During the Coronavirus Disease 2019 Pandemic: A Systematic Review and Meta-Analysis. Frontiers in Psychology. 2020;11:617001.